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Polycystic kidney disease (PKD) is characterized by excessive enlargement of the kidney, 
due to the hyperplastic growth of renal epithelial cells, giving rise to fluid-filled cysts. 
Autosomal dominant PKD (ADPKD), the most common renal disorder, affects 12.5 million 
people and accounts for 10% of the patients receiving renal replacement therapy. In PKD, the 
cyst-lining epithelia display several molecular patterns characteristic of tissue development and 
repair. The expanding cysts are associated with aberrant proliferation and extensive extracellular 
matrix (ECM) remodeling and deposition, causing interstitial fibrosis, which results in the 
progressive decline of renal function in PKD patients. Our lab discovered that periostin, a 
matricellular protein involved in tissue repair, is highly overexpressed in kidneys of human 
ADPKD, Autosomal Recessive PKD (ARPKD) and several animal models of PKD. Periostin 
accumulates in the ECM adjacent to cysts and binds to the cell surface integrins to stimulate the 
proliferation of cystic cells. Genetic knockout of periostin in pcy/pcy mice, a slowly progressive 
model of PKD, significantly reduced cystic growth and fibrosis, demonstrating that periostin 
significantly contributes to the progression of renal cystic disease. The molecular mechanisms 
behind periostin-induced ADPKD progression remain unclear. Here, we show that periostin 
stimulates integrin-linked kinase (ILK), a scaffold protein essential for ECM-cell 
communication, leading to activation of the Akt/mTOR pathway and proliferation of human 
ADPKD cells. In addition, periostin induced the activation of focal adhesion kinase (FAK) and 
Rho-dependent actin stress fiber formation and migration of ADPKD cells. Periostin also 
regulates the expression of genes involved in integrin signaling, ECM deposition and 
cytoskeletal reorganization in ADPKD cells, consistent with periostin activation of cellular 
pathways involved in tissue repair. To determine if overexpression of periostin in the cyst-lining 
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cells accelerates PKD progression, we generated pcy/pcy mice with selective overexpression of 
periostin in the collecting duct (CD) cells, the predominant site of cyst formation. CD-specific 
periostin overexpression accelerated the progression of cystic disease by significantly increasing 
renal mTOR activity, cell proliferation, cyst growth and interstitial fibrosis. In parallel studies, 
we found that pharmacologic inhibition and shRNA knockdown of ILK prevented periostin-
induced Akt/mTOR signaling and ADPKD cell proliferation. Furthermore, selective knockdown 
of ILK in the CD cells of Pkd1fl/fl;Pkhd1-Cre mice, a rapidly progressive model of ADPKD, and 
in pcy/pcy mice, decreased renal Akt/mTOR activity, cell proliferation, cyst growth, and 
interstitial fibrosis, and significantly improved renal function and survival. Our results indicate 
that aberrant expression of periostin stimulates ILK-Akt-mTOR mediated cell proliferation, 
FAK-Rho mediated cytoskeletal rearrangement and migration, and ECM production. We 
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CHAPTER 1. PATHOPHYSIOLOGY OF AUTOSOMAL DOMINANT        
POLYCYSTIC KIDNEY DISEASE  
1.1. Polycystic Kidney Disease  
“Though of simple design, epithelial cysts are, arguably, the most important 
multicellular biological structures in medicine. Every one of us was once a cyst – a 
blastocyst” - Jared. J. Grantham 13. 
Polycystic kidney disease (PKD) is a genetic disorder characterized by a persistent 
growth of fluid-filled cysts in the kidney leading to massive enlargement, often culminating in 
end-stage renal disease (ESRD) 13. A normal adult kidney weighs less than one-third of a pound; 
by contrast, PKD kidneys can weigh over 25 lbs. (Figure 1). There is a wide variability in the 
onset, progression, and severity among individuals affected by PKD. There are two PKD 
subtypes based on genetic inheritance: autosomal dominant PKD (ADPKD) and autosomal 
recessive PKD (ARPKD).  
ADPKD is the more prevalent, slowly progressive form of PKD and is caused by 
mutations in PKD1 and PKD2 encoding for polycystin-1 (PC1) and polycystin-2 (PC2) 14, 15. 
ARPKD is the more severe, early-onset form of PKD and is associated with mutations in 
PKHD1, which encodes the protein fibrocystin/polyductin 16-19, causing dysregulation in cellular 




















Figure 1-1. Images of normal and ADPKD kidneys. (A) A normal human kidney is typically the size of 
a human fist. (B) By contrast, an ADPKD kidney is the size of a football. Picture courtesy of PKD 
Biomarkers and Biomaterials Core in the Jared Grantham Kidney Institute at the University of Kansas 
Medical Center. 
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1.2. Autosomal Dominant Polycystic Kidney Disease (ADPKD)  
ADPKD is the most prevalent monogenic disorder that affects around 12.5 million people 
worldwide 20. It occurs more commonly than sickle cell anemia, cystic fibrosis, Huntington’s 
disease and muscular dystrophy combined. Cysts arise from all segments of the nephron but are 
predominantly derived from the collecting ducts (CDs) 21. The cysts appear to be benign 
neoplasms that arise due to epithelial cell proliferation and fluid secretion, leading to massive 
enlargement of the kidneys to about 4-8 times the normal size 1, 22. Growth of the cysts causes 
damage to the neighboring tubules, impeding renal function 7. Expanding cysts are associated 
with a thickened tubular basement membrane due to excessive deposition of extracellular matrix 
(ECM), replacing normal parenchyma with fibrosis, leading to renal insufficiency 23. While cyst 
formation begins in utero, ADPKD is typically slowly progressive with many patients remaining 
asymptomatic for the first 25 years. Approximately 50% of the patients progress to ESRD by 60 
years of age 24. ADPKD is a systemic disorder - vascular abnormalities and cysts in the liver, 
pancreas, seminal vesicles and arachnoid membrane, are associated complications of ADPKD. 
Hypertension is a key symptom and complication of ADPKD and may precede the clinical 
disease manifestations. Patients suffer from reduced quality of life due to flank pain, 
nephrolithiasis and cyst-related complications of the kidney including infections, hemorrhage, 
and hematuria.  
PKD1 mutations account for 85% of the reported cases and patients progress towards 
ESRD by 58 years of age. Within the PKD1 mutations cohort, individuals with truncating 
mutations are affected more severely, progressing towards ESRD by ~55 years, compared to 
patients with non-truncating mutations with a median age at ESRD onset of 67 years. PKD2 
mutations account for most of the remaining 15% of the ADPKD patients. Although individuals 
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with PKD2 mutations show similar systemic manifestations as seen with PKD1 mutations, the 
onset and disease progression is slower, and patients have longer renal survival rates (typical age 
of ESRD onset is ~79 years) and have fewer complications 25, 26. ADPKD accounts for 6-10% of 
the ESRD patients receiving renal replacement therapies. Based on a study performed between 
2007 -2009, total health care costs for ADPKD patients were estimated to be more than USD $2 
Billion per year in the US, averaging about USD $51,048 per patient/year 27. 
Currently, there is no FDA approved treatment for ADPKD. The slowly progressive 
nature of the disease necessitates the use of long-term therapeutic interventions and hence 
potential treatment options need to be safe with minimal side effects.  
 
1.3. Genetics of ADPKD 
PKD1 has 46 exons with a long coding sequence of 12,912 bp (NM_001009944.2) and is 
located on chromosome 16p13.3. The region spanning exons 1 to 33 is duplicated, generating six 
pseudogenes that are located on the same chromosome 15, 28, 29. Additionally, PKD1 has a high 
GC content. These complexities necessitate long-range PCRs followed by nested PCRs to 
analyze specific mutations, making the process time-consuming and technically demanding. 
Despite this, a staggering 868 pathogenic PKD1 mutations, mostly from unique pedigrees, and 
registered in the ADPKD mutation database (http://pkdb.mayo.edu; as of March 2017). PKD2 is 
located on chromosome 4q21 14 and is composed of 15 exons with a coding sequence of 2,907 bp 
(NM_000297.3). 162 PKD2 pathogenic mutations have been identified. All the cells in an 
ADPKD patient harbor the heterozygous PKD mutation; however, cysts arise only from a few 
nephrons, suggesting that a second hit is necessary to initiate cyst formation in the kidney 21. 
Qian et al. 30 isolated human cystic epithelial cells and showed that they harbored a somatic 
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mutation in the other PKD allele, consistent with the concept of a second hit. Supporting this 
observation, mice carrying a hypermutable Pkd2 allele develop cystic disease due to loss of 
function 31. More recently, mice with hypomorphic Pkd1 alleles and reduced expression of 
normal PC1 (15–20%) also developed cystic disease 32, 33, demonstrating that a somatic mutation 
is not required for cyst initiation. The presence of incompletely penetrant, hypomorphic PKD1 
alleles (PKD1p.R3277C) causes a folding/trafficking defect lowering PC1 expression, and 
initiates cyst formation in humans and mice, demonstrating that a reduction in the expression of 
the polycystins below a certain threshold is sufficient to induce the cystogenic pathway (Figure 
1-2). The presence of homozygous hypomorphic PKD1 alleles resulted in a moderate to severe 
ADPKD phenotype in humans and mice 34, 35. Patients that harbored a hypomorphic mutation in 
trans with an inactivating PKD1 allele displayed ARPKD like phenotype with aggressive and 
early cystic disease 36. Thus, the ‘dosage’ of polycystin appears to be critical for the onset and 
severity of the cystic phenotype. Further, the initiation and progression of the cystic disease is 
vastly affected by the timing at which polycystin expression/function is reduced/lost. In an 
elegant study, Piontek et al. 37 showed that inactivation of the Pkd1 gene within the postnatal day 
(PN) 13, induced rapid and aggressive cystic disease. By contrast, Pkd1 knockout after this time 
point resulted in delayed cyst formation and slowly progressive disease. It appears that 
developmental and proliferative genes dramatically change before and after this window of time, 
and the expression of polycystins may be critical at this stage. Further, the timing of polycystin 
loss could be influenced by genetic modifiers, and environmental factors, thus governing the 
course of cyst development. Thus, the threshold expression of the polycystins and the timing at 













Figure 1-2. Polycystin gene dosage influences the cystic phenotype. PC1 levels (bottom) appears to 
directly influence cystogenesis. A ~50% reduction in PC1 expression, with 2 incompletely penetrant 
alleles (R3277C), is associated with adult onset disease. Inheriting an incompletely penetrant PKD1 allele, 
in trans with an inactivating PKD1 mutation, leads to more aggressive cystic disease. Adapted from 
reference 3.  
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1.4. The Polycystins 
PC1 is an integral membrane protein that is thought to interact with PC2, a Ca2+ 
permeable cation channel, and regulate its activity (Figure 1-3). It has a large extracellular N-
terminal region of about 3000 amino acids, containing unique domains and motifs, eleven 
transmembrane domains, and a small C-terminal cytosolic tail 3, 15, 29, 38. The extracellular region 
contains 1) a signal peptide, 2) two leucine-rich repeats (LRR), thought to be involved in cell 
adhesion, 3) a WSC domain responsible for interaction with carbohydrates, 4) a type-C lectin 
motif, likely to participate in cellular signaling and exocytosis, 5) an LDL-A domain, 6) a PKD 
domain with 16 immunoglobulin-like repeats which is thought to make the extracellular tail 
highly extensible, suggesting that PC1 may be involved in mechanical coupling of cells, 7) a 
region homologous to the sea urchin receptor for egg jelly (REJ) that extends over 1000 amino 
acids, potentially involved in ion transport, and 8) the GAIN (G protein-coupled receptor-
autoproteolysis inducing) regulatory domain that contains a G protein–coupled receptor 
proteolysis site (GPS) motif 39-41. GPS-cleavage of PC1 generates an N-terminus and C-terminus 
product (composed of the TM domains and the C-terminal tail), which may remain non-
covalently bound to each other 42. Missense mutations in the GPS domain that prevent the 
cleavage event have been reported in human ADPKD. GPS cleavage of PC1 is not seen in all 
cell types, and both the cleaved and uncleaved forms coexist in the cells; however, PKD1-GPS 
cleavage mutant mice develop an aggressive postnatal cystic disease suggesting that the loss of 
cleaved PC1 promotes cyst formation 43. Between the transmembrane domains, there is a highly-
conserved lipoxygenase α-toxin (PLAT) domain which appears to be involved in lipid/protein 
binding potentially integrating PC1 signaling and trafficking 44, 45. PC1 shares many conserved 
motifs with the egg jelly receptors, including the PKD repeats, GPS, REJ, C-type lectin, PLAT 
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and the transmembrane domains, suggesting that PC1 could be a cell surface receptor 46.The C-
terminal tail of PC1 contains a coiled-coil (CC) domain that aids in interaction with PC2, and a 
domain for binding heterotrimeric G-proteins 38, that activates transcription factors such as 
nuclear factor of activated T-cells (NFAT) and AP-1, regulating signaling pathways including, 
mammalian target of rapamycin (mTOR), JNK, WNT, JAK/STAT, and intracellular calcium 
signaling 47-50. In vitro, the C-terminal tail can be phosphorylated by PKA 51, 52, and could also 
interact with protein phosphatases, possibly altering the phosphorylation state of PC1, PC2 and 
other proteins 53. Furthermore, it appears that proteolytic cleavage of the C-terminal tail can lead 
to its translocation to the nucleus, directly regulating gene expression 54.  
PC2 shows high sequence homology to transient receptor potential (TRP) channel 
proteins and is also referred to as TRP2. Several groups have shown that it functions as a non-
selective Ca2+ permeable channel 55-58. PC2 also forms tetrameric structures with other TRP 
channels 59. PC2 contains 1) 6 transmembrane helices that display high permeability to Ca2+ ions, 
a cytoplasmic C-terminal tail including 2) a G-protein activating peptide (GPAP), 3) an 
endoplasmic reticulum retention (ERR) signal, 4) a coil-coiled (CC2) domain that is thought to 
mediate its C-terminal oligomerization and bind to PC1 C-terminus 56, 5) a Ca2+ binding EF-
hand domain that regulates Ca2+-dependent interactions 60, and 6) the N-terminus, which is 
relatively small and faces the cytosol, in contrast to the N-terminus of PC1.Very recently, three 
groups have deciphered the cryo-EM structures of PC2 in different conformational states, and 
have shown that it can exist in single or multi-ionic states and can reciprocally regulate, as well 
as be regulated by Ca2+ binding 58, 61, 62. The lipid composition at various PC2 localization sites 
may also potentially regulate its functional conformation states. 
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PC1 is expressed in most organs including the kidney, brain, liver, pancreas, heart, and 
lungs. It is localized in the focal adhesions, membrane junctions such as desmosomes, tight 
junctions, and adherens junctions, apical vesicles, primary cilia, endoplasmic reticulum (ER), 
and the urinary exosomes 3, 63-66. Polycystin-2 predominantly localizes to the ER. Other sites of 
PC2 expression are the basolateral membranes, primary cilia, mitotic spindles, lamellipodia and 
the urinary exosomes. The differential localization of PC1 and PC2 suggest that they may also 
act independently. Although mutations in PKD1 or PKD2 causes low intracellular Ca2+, the 
primary sites of the TRP2 channel activity and its regulation by PC1 remain unclear 1. 
Considering the literature on the coupling and interaction of TRP channels in the plasma 
membrane and receptors like inositol-1,4,5 triphosphate (IP3) in the ER, it is possible that PC1 in 
the plasma membrane and PC2 in the ER may interact and capacitate calcium signaling 55, 67, 68. 
Both PC1 and PC2 may localize to the primary cilium to maintain mechanosensation. However, 
it was recently shown that the cilia are not calcium-responsive mechanosensors 69. It is possible 






Figure 1-3. Proposed structures of PC1 and PC2. Reproduced with permission from reference 6. PC1 
has 11 transmembrane domains with a large N- terminal extracellular domain, and a short cytoplasmic C-
terminal tail. The coiled coil (CC) domain in the C-terminal end of PC1 interacts with the C-terminal tail 
of PC2. PC2 has cytoplasmic N and C-terminus and 6 transmembrane domains. 
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1.5. Mechanisms of cyst formation 
1.5.1. Role of cAMP 
In ADPKD, cyst formation is characterized by abnormal cell proliferation and fluid 
secretion. The tubule epithelial cells relentlessly proliferate, stretching the tubule walls and 
accumulate the non-reabsorbed luminal fluid. These microcysts expand and eventually bud away 
from the parent tubule to become isolated cysts. The exact molecular mechanisms responsible for 
cyst formation remain unclear 71. It appears that the dysregulation of the polycystin complex 
disrupts Ca2+ homeostasis, reducing intracellular Ca2+ levels. Primary ADPKD cells derived 
from human cyst epithelium have lower baseline Ca2+ compared to normal human kidney (NHK) 
cells 72. Interestingly, there is elevated levels of the second messenger, 3’, 5’ cyclic adenosine 
monophosphate (cAMP) in cystic epithelial cells of PKD kidneys 73-75. cAMP is anti-mitogenic 
to NHK cells; by contrast, cAMP increases ADPKD cell proliferation by phosphorylation of 
extracellular signal-regulated kinase (ERK), a mitogen-activated protein kinase (MAPK). The 
addition of a Ca2+ channel activator or a Ca2+ chelator prevented the cAMP-mediated 
proliferative response in ADPKD cells 72, 76, 77. Further studies showed that in NHK cells, BRAF, 
a kinase that regulates MEK/ERK signaling, is repressed by a Ca2+-dependent mechanism, 
preventing cAMP activation of the MEK/ERK pathway and cell proliferation. By contrast, in 
ADPKD, low intracellular Ca2+ relieves BRAF inhibition, allowing cAMP stimulation of the 
BRAF/MEK/ERK pathway and cell proliferation 78, 79(Figure 1-4).  
cAMP also induces PKA phosphorylation of the cystic fibrosis transmembrane 
conductance regulator (CFTR), causing secretion of chloride (Cl) into the lumen leading to fluid 
accumulation in the cysts 1, 80, 81. Pkd null embryonic kidneys showed cAMP-mediated formation 
of cyst-like tubule dilatations in organ culture; by contrast, Cftr and Pkd double knockout 
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embryonic kidneys did not form these cystic structures in the presence of cAMP 82. Taken 
together, these results suggest that cAMP promotes ERK-mediated cell proliferation and Cl-
dependent fluid secretion.  
Arginine vasopressin (AVP) is a key cAMP agonist for the kidney. Binding of AVP to 
the vasopressin V2 receptors (V2R) on the renal CD cells causes increased cAMP and PKA-
mediated phosphorylation of aquaporin-2 (AQP-2). This activated AQP-2 is inserted into the 
apical membrane, leading to increased water reabsorption and a concentrated urine. Upon 
hydration, plasma AVP levels drop resulting in a diluted urine. ADPKD patients have elevated 
V2R and circulating AVP, yet many patients have a compromised concentrating capacity, likely 
due to the disruption of the renal architecture 74, 75, 83. Gattone and colleagues 75, 83, 84 reasoned 
that V2 receptor inhibition would decrease cAMP-mediated cyst growth in PKD. They 
administered OPC-31260, a V2R inhibitor, to 1) cpk/cpk mice, an aggressive model of recessive 
PKD, 2) pcy/pcy mice, a slowly progressive model of PKD, 3) PCK rats, an orthologous model 
of ARPKD and 4) Pkd2WS25/- mice, a slowly progressive orthologous model of ADPKD. 
Inhibition of V2R dramatically slowed cyst growth and preserved renal function in all these 
models, suggesting that AVP is a key modulator of cAMP-mediated cyst growth. Further, in an 
elegant study, Nagao et al. 74 found that increased water intake in PCK rats also mirrored the 
effects of V2R inhibition and showed a marked reduction in cystic disease. Using a genetic 
approach, Torres and associates crossed the Battleboro rats, which lack AVP, to the PCK rats 85 
to show that AVP depletion reduces cystic disease similar to increased water intake. Further, 
administration of vasopressin analog (DDAVP) to the AVP depleted PCK rats, restored the 
cystic phenotype, highlighting that AVP and cAMP are key modulators of cystogenesis. OPC-
41061 or tolvaptan, a highly selective potent V2R inhibitor, also shown to reduce PKD in animal 
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studies 86, was tested in a three-year double blinded, placebo-controlled clinical trial (TEMPO) 
for ADPKD. Although some patients were discontinued due to complications from aquaresis or 
elevated liver enzyme levels, the drug was found to reduce total renal volume and improve renal 
function 87.  
The balance involved in cAMP production by adenylyl cyclases (ACs) and its 
degradation by phosphodiesterases (PDEs) can be perturbed by the low intracellular Ca2+ in 
ADPKD. Ca2+-regulated ACs and PDEs can locally or globally alter cAMP. Earlier work from 
our lab showed that ADPKD cells have increased calcium-inhibited ACs 5/6; however, cAMP 
mediated cell proliferation appeared to be more dependent on the Ca2+/calmodulin-stimulated 
AC3, suggesting that there was a change in the regulation of the AC isoforms 88. Consistent with 
these findings, others have shown that conditional deletion of AC6 significantly reduces cystic 
disease 89. Further, expression and activity of the PDE isoforms influence global and 
compartmentalized cAMP pools. We found altered regulation of the PDE isoforms in ADPKD 
90. The expression of PDE3 and PDE4 were reduced in ADPKD cells, compared to NHK cells. 
PDE4 was involved in alterations in global intracellular cAMP and chloride secretion, whereas, 
the Ca2+/calmodulin-regulated PDE1 was specifically affected AVP-induced activation of the 
BRAF/MEK/ERK pathway and ADPKD cell proliferation. Consistent with these findings, 
knockout of Pde1a, Pde1c, or Pde3a accelerated PKD progression in Pkd2 mutant mice. 
Furthermore, Glycogen synthase kinase 3 beta (GSK3β), a serine-threonine kinase, can promote 
cAMP production by modulating AC activity, and there is an abnormal expression of GSK3β in 
ADPKD, which promotes cAMP-mediated cyst expansion. Recently, it has been shown that 
cAMP can also regulate GSK3β expression, thereby resulting in a feed-forward mechanism in 












Figure 1-4. Proposed mechanism for cAMP-mediated cell proliferation. Redrawn from reference 1. (A) 
cAMP inhibits ERK and proliferation of normal human kidney cells. In normal cells, BRAF is repressed 
by a Ca2+-dependent mechanism, preventing cAMP activation of ERK B) By contrast, cAMP agonists, 
stimulate the MEK/ERK pathway and proliferation of ADPKD cells. Mutations in the PKD genes reduce 
intracellular Ca2+ de-repressing BRAF, resulting in cAMP-dependent cell proliferation and cyst growth.  
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1.5.2. Role of growth factor signaling 
Epidermal growth factor receptor (EGFR; Erb-1) and Erb-B2, belong to the receptor 
tyrosine kinase (RTK) family and are aberrantly expressed in PKD. They bind to the epidermal 
growth factor (EGF) and stimulate cell proliferation via the MEK/ERK pathway. Although renal 
EGF expression is downregulated in some animal models of PKD, mitogenic concentrations of 
EGF-like peptides have been identified in cyst fluids from human ADPKD, ARPKD and rodent 
PKD 94, 95. Inhibition of EGFR and Erb- B2 activity appears to reduce cystic disease in several 
rodent models of PKD 96-99. ERK inhibition also slowed cystic disease progression in pcy/pcy 
mice; however, MEK inhibition did not affect cyst growth in an aggressive model of cystic 
disease 100, 101. Interestingly, inhibition of Src, a tyrosine protein kinase downstream of RTKs, 
reduces cystic disease in bpk mice and PCK rats. Effects of long-term inhibition of RTK 
signaling remains to be determined.  
 
1.5.3. Role of mTOR in ADPKD 
The mammalian target of rapamycin (mTOR) complex regulates cell proliferation, cell 
growth, and protein translation by phosphorylating 4E‐BP1 and the p70 ‐ S6 kinase (S6K), 
regulators of translation initiation and ribosomal function.  
The tuberous sclerosis complex (TSC) proteins hamartin and tuberin (encoded by TSC1 
and TSC2, respectively), regulate mTOR activity. The TSC genes themselves appear to be 
important cystogenic modifiers of ADPKD. TSC2 and PKD1 lie in a tail-to-tail orientation 102 in 
the human genome. Tuberous sclerosis is associated with renal lesions, and epithelial cysts and 
some TSC patients who have ADPKD are thought to have a contiguous gene syndrome due to 
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loss of expression of TSC2 and PKD1 103. In rodents, inactivation of TSC1 or TSC2 leads to renal 
cysts potentially through downregulation of PC1 expression 104, 105. At the protein level, tuberin 
functions as a GTPase activating protein (GAP), and hamartin binding regulates its GAP activity. 
Tuberin maintains Rheb, a GTP-binding protein in its inactive state. Inactivation of the 
tuberin/hamartin complex by mechanisms including AKT or ERK-mediated phosphorylation of 
tuberin releases Rheb which in turn activates mTOR 106.  
PC1 appears to bring tuberin and mTOR proximal to each other by forming a complex, 
hence inhibiting mTOR, and functional loss of the polycystins leads to aberrant activation of the 
Akt/mTOR signaling pathway 48, 107-109. Inhibition of mTOR using rapamycin or its derivatives 
reduces cystic disease and fibrosis in several murine models of PKD, suggesting that mTOR 
activation is a common phenomenon in renal cystic diseases 4, 109-113. While clinical trials for 
mTOR inhibitors in PKD did not yield promising results, limiting factors including the use of 
suboptimal doses, recruitment of patients who had already progressed to stage III chronic kidney 
disease (CKD), and discounting the effects of reduction in total kidney volume, may have 
affected the outcomes 114.  
 
1.6. Futile repair in PKD  
Many developmental genes and signaling pathways are aberrantly regulated in PKD, and 
cystic epithelial cells are thought to be incompletely differentiated 115, 116. In a detailed review, 
Tran et al. 117 proposed that dysregulation of developmental pathways including the Hedgehog, 
Wnt and Notch pathways may play a key role in renal cystogenesis. Song et al. performed a 
genome-wide expression analysis to study the genes and pathways differentially regulated in 
human ADPKD 118. They found that several genes involved in epithelial differentiation, integrin-
 16 
ECM signaling, growth factor-induced proliferation, fibrosis, and inflammation, were altered in 
ADPKD. Weimbs and colleagues 106, 119, 120 postulated that mutations in the polycystins might 
initiate uncontrolled activation of renal repair pathways, including mTOR, that promote cell de-
differentiation, cytoskeletal reorganization and proliferation, hallmarks of cystic disease. 
Interestingly, several independent groups showed that an external renal injury accelerates cystic 
disease progression in slowly progressive murine models of PKD 121-125. Thus, the loss of 
polycystin function perhaps predisposes the cells to form cysts when presented with an insult or 
a mitogenic modifier. Additionally, the process of cyst expansion along with inflammation and 
fibrosis may compress the neighboring nephrons, activating repair programs that could initiate 
additional cyst formation. Identifying and targeting such maladaptive repair pathways can lead to 










CHAPTER 2. ECM-INTEGRIN SIGNALING 
2.1. The extracellular matrix dynamics during repair and disease 
The extracellular matrix (ECM) was originally conceptualized as a structural scaffold for 
the cells that provides tissue integrity. Recently, the ECM has been recognized as a dynamic 
structure that undergoes constant remodeling to maintain tissue homeostasis 126. The ECM is an 
elaborate and complex assembly of 1) fibrous structural proteins, including collagens, laminins 
and fibronectins, 2) specialized proteins such as growth factors, matricellular proteins, and 3) 
proteoglycans, which interact with the cell surface receptors and integrins. The composition of 
the ECM is also highly dynamic and depends on the localization and state of the tissue or cell 
type. It undergoes rapid remodeling during tissue development and repair in response to external 
stimuli that are transmitted to the cell through integrins, syndecans, and laminin receptors, and 
other receptors located on the plasma membrane 127. The ECM is an important part of wound 
healing 128; however, excessive matrix deposition leads to fibrosis, a common feature of chronic 
kidney disease 129. ECM components also undergo proteolytic cleavage during remodeling by 
proteinases including matrix metalloproteinases (MMPs), and other serine and cysteine 
proteases. They cleave structural molecules, release small peptides and growth factors, and can 
directly affect degradation of matrix proteins. Unchecked MMP activity is also noted during 
injury and fibrosis.  
Matricellular proteins represent a family of soluble ECM molecules that regulate collagen 
fibrillogenesis and bind to heterodimeric integrin receptors, facilitating communication between 
the cell and the ECM 130, 131. Integrin engagement leads to the formation of cellular focal 
adhesion junctions, characterized by the aggregation of cytoskeletal proteins including focal 
adhesion kinase (FAK), integrin-linked kinase (ILK), and paxillin, activating pathways involved 
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in cell adhesion, migration, and proliferation. Thus, ECM proteins regulate intracellular 
dynamics, a process called “outside-in signaling” 132-134. Persistent expression of these proteins is 
associated with chronic inflammation and tissue fibrosis 8, 23, 135-138.  
 
2.2. Dysregulation of ECM signaling in PKD 
The concept of altered ECM signaling in PKD arose from earlier observations that the 
basement membranes of the cysts appeared thickened and abnormal139-141. Since then, aberrant 
expression of ECM molecules and integrin receptors have been reported in several human and 
rodent models of PKD2, 142, 143. While the PKD genes could themselves cause dysregulated ECM 
production 144, increasing literature suggests that abnormalities in the matrix are not seen before 
cyst initiation, rather, they may arise due to factors produced by the cysts (Figure 2-1) 2, 7, 23, 116. 
Thickening of the tubular basement membrane due to deposition of ECM, and increased 
accumulation of fibroblasts and inflammatory cells in the interstitium are the forerunners of 
fibrosis in ADPKD. Indeed, fibrosis causes loss of functional renal parenchyma and leads to end 
stage renal disease (ESRD). Currently, the molecular mechanisms leading to aberrant ECM 
signaling and its role in PKD progression remain unclear.  
Among factors that govern ECM composition and turnover, MMPs appear to be 
dysregulated in PKD. The expression of MMP2 was decreased in the Han:SPRD Cy/+ rat, a 
nonorthologous model of ADPKD 145. By contrast, MMP14 was found to be upregulated in the 
cyst-lining epithelia. Batimastat, an MMP inhibitor, reduced cystic disease progression in this rat 
model146. Murine PKD kidneys showed increased expression of MMPs147, 148. Consistent with 
these observations, serum samples from human PKD patients also showed elevated MMPs 149, 
150. It is speculated that breakdown of matrix molecules can induce an immune response. For 
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instance, breakdown of collagen I into a proline-glycine-proline (PGP) fragment, is thought to 
drive the progression of chronic obstructive pulmonary disease 151. In sum, these data suggest 
that matrix-degrading proteases may contribute to PKD progression, although their functional 
relevance remains to be determined. 
Several integrins, including αV, α8, β1, and β4, are aberrantly expressed by cyst-lining 
cells in PKD 2, 143, 152-154 and deletion of β1- integrin prevented cystogenesis in a Pkd1 mutant 
mouse model 154. We and others have shown that abnormal and extensive expression of ECM 
molecules, including laminins, collagens, and matricellular proteins, accelerate cyst growth 
through activation of integrin signaling 2, 23, 118, 143, 155. Laminin-332 (α3, β3, γ2), also called 
laminin-5, has been shown to be abnormally expressed in PKD and contributes to cell adhesion 
















Figure 2-1. Factors affecting ADPKD progression. Reproduced with permission from reference 7. (A) 
Hematoxylin and eosin stained section from Han:SPRD Cy/+ rat, showing the transition between a cyst 
and the neighboring tubules (asterisk). Thickened tubule basement membrane and ECM beneath the 
tubule, labeled as 'cystic transformation'. (B) Immunohistochemical staining shows that phosphorylated 
ERK (pERK; arrows) exclusively stains the cystic portion of the hemi-cyst. (C) An expanding cyst 
associated with thickened basement membrane material. Macrophages and fibroblasts, and ECM 




2.3. Periostin - the multifaceted matricellular molecule 
2.3.1. Structure of periostin and its functions in normal physiology and pathophysiology 
Periostin, known originally as osteoblast-specific factor-2156, was discovered and 
identified in a mouse osteoblast cell line. The protein was later renamed periostin because of its 
predominant expression in the periosteum and the periodontal ligament 157. Human periostin is 
located on chromosome 13q, while murine periostin is located on chromosome 3158. It is a 90 
kDa secreted glycoprotein (Figure 2-2) composed of 1) an amino-terminal secretory sequence, 
2) an EMI domain, 3) four fasciclin1 (Fas1) domains with structural homology to the insect axon 
guidance protein fasciclin1 and the Drosophila adhesion protein Fas1, and 4) a carboxyl-terminal 
domain (CTR) 8. Periostin also shares structural homology to a 68 kDa protein - transforming 
growth factor (TGF)-β-induced gene clone 3 (βig-H3) 159. The EMI domain is cysteine-rich and 
is responsible for protein-protein interactions, enabling periostin to interact directly with proteins 
including βig-H3 160, collagen type I 161 and fibronectin 162. Fas1 domains 2 and 4, contain a 
central Asp-Ile amino acid dimer that appears to bind αVβ3, and αVβ5 integrin receptors. This 
binding motif is conformationally similar to the traditional integrin-binding RGD motif 163, 164. 
Additionally, the Fas1 domains also bind to an array of cell adhesion proteins including tenascin-
C and bone morphogenic protein-1 (BMP-1) 165. These potential protein interactions involving 
periostin underline its importance as a cell adhesion and migration molecule. The CTR domain 
of periostin, containing exons 15-23, is the least conserved region across species and is the least 
studied. It contains a heparin binding site, several proteolytic cleavage sites that can give rise to 
different splice variants, and a puzzling nuclear localization signal, which is at odds with 



















Figure 2-2. Key structural domains of periostin. Periostin is a 90 kDa secreted glycoprotein composed 
an amino-terminal secretory sequence (SS in A; yellow box in B), an EMI domain, four fasciclin1 (Fas1) 
domains, and a carboxyl-terminal domain (CTR) with several proteolytic cleavage sites that can give rise 




Periostin is expressed in tissues involved in mechanical stress, such as periodontal 
ligaments, periosteum, and cardiac valves; and is secreted into the ECM following acute injury to 
heart, skin and other tissues 157. It directly interacts with components of the ECM, including 
collagen and fibronectin, and promotes collagen cross-linking through activation of lysyl 
oxidase167, 168. Periostin-induced fibrillogenesis is important to maintain tissue integrity 161. In 
addition to modulating biomechanical properties of tissues, periostin binds αV-integrins on the 
cell surface and activates cellular pathways involved in 1) cell proliferation, 2) survival, 3) 
profibrotic TGF-β signaling, and 4) angiogenesis 2, 8, 137, 164, 169-171. Application of periostin to 
cardiac tissue, following an infarction, stimulates proliferation of differentiated cardiomyocytes 
leading to myocardial repair 172, 173.  
Global periostin knockout mouse (Postn-/-) 174 was generated by inserting a lacZ reporter 
gene at the first exon site in the mouse periostin gene, and subsequent studies elucidated the role 
of periostin in development and disease 131, 135. Postn-/- mice are viable and appear normal at 
birth. However, ~ 15% of the mice die before weaning age (2-3 weeks), potentially due to 
valvular insufficiency. Upon examination, valve leaflets of the Postn-/- mice displayed large 
acellular ECM deposits and ectopic smooth muscle cell clusters 174. Norris et al. observed that 
adult Postn-/- mice had a reduction in skin thickness and tensile strength, potentially due to a 
reduction in crosslinking of type I collagen fibers in the skin 161. These mice also exhibited mild 
growth retardation and early onset periodontal disease, coupled with incisor enamel defects 174. 
A soft diet regime partially rescued the growth retardation in the Postn-/- mice by reducing the 
mechanical strain on the periodontal ligament. These observations suggest that periostin plays 
important roles in ECM maturation and organization.  
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Periostin is overexpressed in several cancers, including lung, ovarian, breast and colon, 
where it binds to αV-integrins (αVβ3, αVβ5), stimulating Akt/mTOR, leading to increased cell 
proliferation, survival, and angiogenesis of the tumor 158, 164, 171, 175-178. Serum periostin is also 
being considered as a potential biomarker for some cancers 179, 180. Aberrant expression of 
periostin, perhaps due to inappropriate tissue adaption to injury, has pathological consequences 
in heart and other tissues, including tissue fibrosis 136, 181-183. Matricellular proteins, such as 
periostin, and their cell signaling pathways are being considered as potential therapeutic targets 
to reduce fibrosis. 
 
2.3.2. Role of Periostin in ADPKD 
Periostin is normally expressed briefly within the nephrogenic zone during renal 
development; however, it does not appear to have a role in the adult kidney 2, 5, 184. Previously, 
we showed that periostin was one of the most highly overexpressed genes (overexpressed 13.6-
fold) in the ECM of ADPKD cells compared to normal human kidney (NHK) cells. Periostin is 
secreted by the ADPKD cyst-lining epithelial cells and accumulates within the extracellular 
space adjacent to the cysts and within cyst fluid (Figure 2-3). Periostin stimulates ADPKD cell 
proliferation, and cell-cycle analysis revealed that the percentage of cells in S and G2/M phases 
were increased with periostin-treatment. However, this mitogenic effect of periostin was not 
observed in NHK cells, suggesting that periostin-induced proliferation was unique to cystic cells 
and that periostin does not induce cyst initiation, but rather promotes cyst progression. ADPKD 
cells have a 9-fold overexpression of αV-integrins, receptors for periostin, compared to NHK 
cells 2. This implies that the specific response to periostin by ADPKD cells can be attributed to 
the altered phenotype of the ADPKD cells, because of the abnormal expression of the integrins. 
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Recently, we showed that periostin was also overexpressed in autosomal recessive PKD 
(ARPKD) and several animal models of PKD, including pcy/pcy mice, cpk/cpk mice, jck/jck 
mice 5 and PCK rats (unpublished observation), suggesting that periostin expression is a general 
feature of PKD regardless of the underlying genetic mutation. Global knockout of periostin in 
pcy/pcy mice, a slowly progressive model of PKD, decreased kidney weight (KW) as a percent 
of body weight (%BW) (Figure 2-4) and interstitial fibrosis (Figure 2-5). There was also a 
decrease in renal mTOR activity, consistent with a reduction in the number of actively 
proliferating cells (not shown) 5. Ablation of periostin also resulted in a significant improvement 
in the survival of pcy/pcy mice. These results highlight that periostin is an important mediator of 























Figure 2-3. Periostin expression in ADPKD and NHK kidneys. (A) Representative section of a human 
ADPKD cyst displaying punctuate staining for periostin in mural epithelial cells (arrow) and robust 
staining in the extracellular matrix lining the basal surface of the cyst. By contrast, periostin was not 






Figure 2-4. Periostin accelerates the progression of cystic disease in pcy/pcy mice. (A) Representative 
images of kidney sections, kidney weight (KW) as %BW, and % cystic area from pcy/pcy;Postn+/+, 
pcy/pcy;Postn+/− and pcy/pcy;Postn−/− mice at 20 weeks of age. (b) Kaplan-Meier curve of 
pcy/pcy;Postn+/+, pcy/pcy;Postn+/− and pcy/pcy;Postn−/− mice. (c) Summary of the age of death. pcy/pcy: 
Postn+/+ mice died at 38.1 ± 2.0 weeks. By contrast, pcy/pcy mice with the loss of one Postn allele 
(pcy/pcy;Postn+/−) survived to 44.4 ± 2.4 weeks and pcy/pcy mice with a complete loss of periostin 
expression survived to 51.4 ± 4.2 weeks (*P < 0.05, compared to pcy/pcy;Postn+/+). Reproduced with 





















Figure 2-5. Periostin promotes renal interstitial fibrosis in pcy/pcy mice. Representative kidney 
sections from (A) Postn+/+, (B) Postn−/−, (C) pcy/pcy: Postn+/+ and (D) pcy/pcy: Postn−/− mice were 
stained with Masson trichrome to visualize interstitial collagen (blue color). All images are the same 
magnification. Bar scale is 100 μm. (e) Fibrosis was determined by visual assessment of the trichrome-
stained slides and represented as % fibrotic area to total area of the whole tissue section. (n = 6 per group) 
Data are means ± SE. Statistical analysis was determined by unpaired t-test. *P < 0.05, compared 




2.4. Integrin-linked kinase signaling 
ILK was originally characterized as a serine/ threonine kinase that phosphorylates and 
interacts with β integrins and mediates integrin signaling. ILK is composed of an ankyrin 
domain, a pleckstrin homology-like motif (PH domain) and a catalytic C-terminal domain 
(Figure 2-6) 185, 186. The PINCH scaffolding proteins bind to the ankyrin domain. The C-terminal 
domain of ILK harbors the integrin binding domain (for β1 and β3 integrin binding) 187and an 
atypical kinase-like domain that also appears to bind α- parvin or β-parvin 188, 189. The ILK-
PINCH-Parvin (IPP) ternary complex is responsible for recruiting focal adhesions components 
that mediate cell migration via actin cytoskeleton remodeling 187. Upon binding ILK, PINCH 
also associates with an adaptor molecule Nck2 to activate receptor tyrosine kinase (RTK) 
signaling 190-192. The PH domain is activated by binding of phosphatidylinositol (3, 4, 5)-
triphosphate (PIP3), the second messenger of phosphoinositide 3-kinase (PI3K) 193. Further, the 
ankyrin domain also binds to the ILK-associated protein, ILKAP, a protein phosphatase which 
can inhibit ILK signaling 194.  
In breast cancer, colon cancer, prostate cancer, malignant melanoma and non-small cell 
lung cancer, ILK activity is upregulated (in a PI3K dependent manner) and correlates with the 
stage and grade of cancer 195-198. Phosphatase and tensin homolog on chromosome 10 (PTEN) is 
a tumor suppressor that is mutated at a high frequency in glioblastomas and is known to regulate 
the phosphatidylinositol-3'-kinase (PI3K), potentially repressing the ILK PH domain. Edwards et 
al. showed that ILK and Akt are aberrantly activated in human glioblastoma cells that harbor a 
loss-of-function PTEN mutation. Treatment of antisense oligonucleotides targeted against ILK 
reduces the growth of the tumors in mice with glioblastoma xenografts 199. 
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2.4.1. Arguments for and against ILK as a bona fide kinase 
Several studies have indicated that ILK can directly phosphorylate proteins and substrates 
in vitro. In-gel kinase assays showed that purified ILK could phosphorylate Akt (serine 473) and 
other substrates such as myosin light chain 20 (MLC-20) and a GSK-3αβ/ crosstide peptide 200-
202. ILK lacks certain conserved residues typically found in catalytic kinase domains 203. These 
finding led to a huge controversy in the field questioning if ILK is a bona fide kinase. Fukuda et 
al. resolved a high-resolution 3D structure of the catalytic domain of ILK fused to the C-terminal 
of α-parvin. This study revealed that the ILK catalytic domain shows characteristics of 
pseudokinase activity, including a non-hydrolyzed ATP in the crystal with an unusual ATP 
orientation, and an abnormal catalytic loop that lacked key catalytic residues 189. However, the 
effect of α-parvin binding on the conformation of kinase domain was not considered. The same 
group also demonstrated using biochemical studies, that minute traces of heterogeneous 
components present in partially purified ILK could lead to false-positive results, compromising 
the validity of in vitro kinase assays 204. In an elegant study, Lange et al. made knock-in mice 
harboring various mutations in the ILK domains and showed that both kinase-dead (S344A) and 
constitutively active (S344D) ILK knock-in mice develop normally, suggesting that the kinase 
activity may not be critical for normal physiological development and function 205. Interestingly, 
they saw that mice that harbored a mutation in the α-parvin binding site (also required for ATP-
binding), displayed renal agenesis. Taken together, it appears that the kinase and the scaffold 
functions of ILK may be interdependent. Resolution of the complete crystal structure of ILK will 
be required to answer this question.  
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2.4.2. ILK signaling in normal physiology and pathophysiology  
Despite the debate on the kinase properties of ILK, it is widely accepted that ILK serves 
as a master regulator of cellular behavior and ECM signaling. The scaffold property of ILK is 
critical for the formation of a multi-protein complex with adaptor proteins PINCH and α/β-
parvin: ILK-PINCH-Parvin (IPP) complex 190, 206. The IPP ternary complex and plays a central 
role in ECM-integrin signaling 192, 207 and is responsible for binding β-integrins to the actin 
cytoskeleton and recruiting focal adhesion components that mediate cell proliferation, survival, 
and migration during tissue repair 187, 189. IPP is critical for the phosphorylation of downstream 
molecules such as Akt and the mitogen-activated protein kinases 208-211. Persistent ILK signaling 
to Akt and mTOR mediates carcinogenic cell proliferation. By contrast, in a mouse model of 
Duchenne muscular dystrophy, overexpression of α7-integrin reduced the muscle pathology by 
upregulating ILK signaling to the Akt-mTOR pathway 212, 213. In summary, ILK is an important 





Figure 2-6. ILK structural domains and interactors. (A) ILK is composed of an ankyrin (ANK) 
domain, a pleckstrin homology-like motif (PH) and a catalytic C-terminal (kinase) domain. The ILK-
PINCH-Parvin (IPP) ternary complex is responsible for recruiting focal adhesions components that 
mediate cell migration via actin cytoskeleton remodeling. Adapted from reference 9. (B) IPP associates 
with Nck2 to activate receptor tyrosine kinase (RTK). Phosphoinositol (3, 4, 5)-triphosphate (PIP3) 




2.5. Specific Aims 
ADPKD is the most commonly inherited renal disorder characterized by hyperplastic 
growth of renal epithelial cells that form fluid-filled cysts, leading to excessive kidney 
enlargement, interstitial fibrosis and progressive decline in renal function 13, 22, 214. Despite recent 
advances in ADPKD, there remains a need for better understanding of the molecular mechanisms 
involved in cyst growth and fibrosis in order to develop targeted therapies. Periostin, a 
matricellular protein, is aberrantly expressed in human ADPKD, ARPKD and several animal 
models of renal cystic disease. Periostin binds components of the extracellular matrix (ECM) and 
promotes collagen fibrillogenesis, leading to fibrosis. It also binds cell surface integrins, leading 
to changes in cell adhesion, migration, proliferation, and survival. We found that periostin 
promotes the proliferation of human ADPKD cystic epithelial cells, but does not affect the 
proliferation of normal human kidney cells 2. Global knockout of periostin in pcy/pcy mice, a 
slowly progressive model of PKD, caused a marked reduction in kidney volume, renal mTOR 
activity, number of proliferating cells, cystic area and renal interstitial fibrosis, and preserved 
renal function 5. Loss of periostin also significantly extended the lifespan of the pcy/pcy mice 
demonstrating that periostin contributes importantly to the progression of renal cystic disease.  
Currently, the cellular mechanism for periostin-induced cyst growth and fibrosis in 
ADPKD remains unclear. We propose that cyst-lining cells are involved in a futile repair 
mechanism causing persistent expression of periostin and activation of ILK signaling, leading to 
aberrant cell proliferation, cyst growth, interstitial fibrosis, and decline in renal function. Our 
long-term goals are to delineate the cellular and molecular mechanisms underlying the mitogenic 
and fibrotic effects of matricellular molecules including periostin, in renal cystic diseases. 
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Aim 1: To determine if knockdown of ILK in human ADPKD cells inhibits periostin-
induced Akt/mTOR signaling and cell proliferation, and slows cyst growth and fibrosis in 
PKD mice (Chapter 3). We employed pharmacologic inhibition and shRNA knockdown of ILK 
in ADPKD cells to determine if the loss of ILK prevents periostin-induced activation of mTOR 
and cell proliferation. Next, we determined if knockdown/knockout of ILK in the collecting 
ducts (CDs), a predominant site for cyst formation, reduced cyst growth and fibrosis in two 
relevant murine models of PKD. 
Aim 2: To determine if periostin promotes cytoskeletal remodeling, cell migration and 
ECM production by human ADPKD cells, and accelerates cyst growth and fibrosis in PKD 
mice (Chapter 4). We hypothesize that aberrant expression of periostin by cystic epithelial cells 
stimulates a futile repair mechanism that promotes cyst growth and fibrosis in PKD kidneys. We 
determined if periostin induced pathways involved in tissue repair, including cell proliferation, 
actin remodeling, ECM-integrin signaling, integrin clustering and the migration of human 
ADPKD cells. To examine the role of periostin in vivo, we generated periostin transgenic mice 






CHAPTER 3. INTEGRIN-LINKED KINASE SIGNALING PROMOTES CYST 
GROWTH AND FIBROSIS IN POLYCYSTIC KIDNEY DISEASE 
3.1. Abstract 
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by innumerous 
fluid-filled cysts and progressive deterioration of renal function. Previously, we showed that 
periostin, a matricellular protein involved in tissue repair, is markedly overexpressed by cyst 
epithelial cells. Periostin promotes cell proliferation, cyst growth, interstitial fibrosis and the 
decline in renal function in PKD mice. Here, we show that the binding of periostin to αV-
integrins stimulates integrin-linked kinase (ILK), a scaffold protein that is essential for linking 
the extracellular matrix to the actin cytoskeleton, leading to activation of the Akt/mTOR pathway 
and proliferation of human ADPKD cells. Pharmacologic inhibition and shRNA knockdown of 
ILK prevented periostin-induced Akt/mTOR signaling and ADPKD cell proliferation. 
Homozygous deletion of ILK in renal collecting ducts (CD) of Ilkfl/fl;Pkhd1-Cre mice caused 
tubule dilations, apoptosis, fibrosis, and organ failure by 10 weeks of age, confirming that ILK is 
critical for maintaining the CD epithelium and renal function. By contrast, Ilkfl/+;Pkhd1-Cre mice 
had normal renal morphology and function and survived beyond one year. Reduced expression 
of ILK in Pkd1fl/fl;Pkhd1-Cre mice, a rapidly progressive model of ADPKD, decreased renal 
Akt/mTOR activity, cell proliferation, cyst growth, and interstitial fibrosis, and significantly 
improved renal function and survival. In addition, CD-specific knockdown of ILK strikingly 
reduced renal cystic disease and fibrosis and extended the life of pcy/pcy mice, a slowly 
progressive PKD model. We conclude that ILK is a key intermediate for periostin activation of 
signaling pathways involved in cyst growth and fibrosis in PKD. 
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3.2. Introduction  
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in 
PKD1 or PKD2, which encode for polycystin-1 and 2, respectively 3. The disorder is 
characterized by the formation of fluid-filled cysts, leading to loss of functional parenchyma, 
interstitial fibrosis, and enlarged kidneys. Several signaling pathways have been implicated in 
PKD 20; however, the mechanisms involved in disease progression remain unclear. Cyst-lining 
cells are characterized as being incompletely differentiated and express factors involved in tissue 
repair 106, 115, 116, 119. Tissue injury caused by compression of neighboring nephrons as cysts 
expand may activate repair mechanisms, including the stimulation of the Akt/mTOR pathway 106, 
215, 216, contributing importantly to cyst growth 119, 120 and formation of new cysts. 
We found that periostin, a matricellular protein involved in tissue repair, was highly 
overexpressed in ADPKD, autosomal recessive PKD (ARPKD) and rodent models of PKD, 
suggesting that periostin expression is a common feature of renal cystic disease 2. Knockout of 
periostin reduced mTOR activity, cyst growth, and interstitial fibrosis, and significantly 
improved the survival of pcy/pcy mice 5.  
 αVβ3-integrins, the receptors for periostin, promote proliferation of cancer cells 176 by 
activating integrin-linked kinase (ILK) 217 and stimulating downstream Akt/mTOR and GSK-
3β/β-catenin signaling pathways 132, 218. ILK interacts with β1- integrin and was originally 
characterized as a kinase 132, 185, 188, 201, 219-221. However, it remains unclear if ILK is a bona fide 
kinase since the kinase domain lacks conserved motifs found in conventional kinases and 
mutations that should render the kinase inactive failed to alter mouse development 187, 188, 204, 205. 
Nevertheless, it is generally agreed that ILK serves as a scaffolding protein critical for the 
formation of a multi-protein complex with adaptor proteins PINCH and α-parvin 190, 206. ILK-
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PINCH-Parvin (IPP) signaling affects phosphorylation of downstream molecules such as Akt 
and the mitogen-activated protein kinases 208-211 and plays a central role in ECM-integrin 
signaling 192, 207. The IPP ternary complex is responsible for binding β-integrins to the actin 
cytoskeleton and recruiting focal adhesion components that mediate cell proliferation, survival, 
and migration during tissue repair 187, 189. ILK activation of Akt and mTOR mediates 
proliferation of cancer cells 212, 213. In addition, PINCH interacts with adaptor protein NCK2, 
leading to crosstalk between the ILK and receptor tyrosine kinase (RTK) pathways 190-192.  
We determined if ILK mediates periostin-induced ADPKD cell proliferation and if 
knocking down ILK in renal collecting ducts (CD) reduces cystic disease in two models of PKD. 
The results indicate that ILK is a key intermediate in the activation of cellular pathways involved 
in cyst growth. We propose that targeting the periostin-integrin-ILK axis may be a potential 
therapeutic approach to slow cyst growth and fibrosis in PKD. 
 
3.3. Materials and Methods  
Human ADPKD and normal human kidney cells. Primary cultures of ADPKD and normal human 
kidneys (NHK) cells were generated by the PKD Biomaterials and Biomarkers Core in the 
Kansas PKD Center at the Kansas University Medical Center (KUMC). ADPKD kidneys were 
obtained from the surgery department at KU hospital and other hospitals participating in the 
Polycystic Kidney Research Retrieval Program through the assistance of the PKD Foundation. 
Normal human kidneys, unsuitable for transplantation, were obtained from the Midwest 
Transplant Network (MTN; Kansas City, KS), an organ retrieval agency. The protocol for the 
use of discarded human tissues for research complies with federal regulations and was approved 
by the Institutional Review Board at KUMC. Primary cell cultures were prepared as described 
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previously 90, 222. Cells were propagated in DMEM/F12 supplemented with 5% FBS, 5 µg/ml 
insulin, 5 µg/ml transferrin, and 5 ng/ml sodium selenite (ITS) and penicillin G and streptomycin 
(P/S). After cells had reached 70-80% confluence in the flasks, they were lifted from the plastic 
with a trypsin-EDTA solution (Sigma Chemical, Saint Louis, MO) and counted using a 
hemocytometer.  
 
Cell Proliferation measurements. ADPKD cells (7.5 × 104) were seeded into individual wells of 
6-well plates containing DMEM/F12, ITS, 1% FBS and P/S. After cells reached approximately 
50% confluence, the serum was reduced to 0.002%. After 24 h, cells were treated with 250 ng/ml 
human recombinant periostin (75 kDa; Biovendor, Asheville, NC) or 100 ng/ml epidermal 
growth factor (EGF; Sigma Chemical) alone or in the presence of 1 μM CPD 22 (EMD 
Millipore, Billerica, MA), an ILK inhibitor 223, for an additional 24 h. Each treatment was 
performed in triplicate. Cells were harvested by trypsinization, counted using an automated cell 
counter (Bio-Rad, Hercules, CA) and normalized to the control-treated group. In some 
experiments, cell proliferation was determined by an MTT assay 224. Briefly, ADPKD cells (4 × 
103) were seeded into the wells of a 96-well plate (six wells per experimental condition) and 
grown under similar conditions as described above. After the 24-h treatment, cell proliferation 
was measured using CellTiter 96 non-radioactive cell proliferation (MTT) assay (Promega, 
Madison, WI).  
 
ILK knockdown in human ADPKD cells. ILK was knocked down in human ADPKD cells using 
shRNA lentiviral approach. Six unique ILK shRNA constructs (RHS4531-EG3611), each with a 
high specificity for the ILK mRNA, and a scrambled non-silencing shRNA construct (RHS4346) 
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were purchased from GE Healthcare (Waukesha, WI). HEK293T cells were transfected with 4.5 
µg ILK or scrambled shRNA plasmid DNA and the packaging vectors (4.5 µg psPAX2 and 1.8 
µg pMD2.G) using Lipofectamine 200 (Invitrogen, Carlsbad, CA). The cells were incubated for 
18 h for lentivirus production. Fresh media was added, and the conditioned media containing the 
lentivirus was harvested at 24 h and 48 h. Human ADPKD cells were seeded into 100 mm petri 
dishes for 24 h. Lentiviral harvest media from the two time points was added successively to the 
ADPKD cells. After viral infection, media bathing the ADPKD cells was switched to DME/F12 
+ 1% FBS for two days. Using immunoblot analysis, ILK knockdown efficiency was determined 
by band densitometry of ILK protein from ADPKD cells infected with ILK shRNA compared to 
the scrambled shRNA. We selected two shRNAs with the best knockdown efficiencies (mature 
antisense sequences for ILK shRNA1: ACACTACGGCTATTGAGTG, and ILK shRNA2: 
ATACGGTTGAGATTCTGGC). Alignment of the reverse complement of the antisense 
sequences targeted only ILK and no other mRNAs. To determine if ILK knockdown inhibits 
periostin-induced cell proliferation, ADPKD cells were infected with individual ILK shRNA or 
the scramble shRNA and then treated with 250 ng/ml periostin or EGF (positive control) for 24 
h. Cell proliferation was determined by either cell count (N = 1) or MTT assay (N = 3).  
 
Collecting duct-specific ILK knockdown and knockout in mice. Ilkfl/fl mice 225 were crossed to 
mice expressing Pkhd1-Cre, which maximally express Cre recombinase in the CD at postnatal 
(PN) day 7 226 to generate Ilkfl/+;Pkhd1-Cre mice. These mice were crossed to produce 
Ilk+/+;Pkhd1-Cre (WT: Ilk+/+ CD), Ilkfl/+;Pkhd1-Cre (Ilk+/- CD), Ilkfl/fl;Pkhd1-Cre (Ilk-/- CD) 
mice. We observed normal Mendelian inheritance. Mice were provided food and water ad 
libitum and monitored daily. At five and 10 wk of age, mice were water-restricted for three h and 
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urine was collected for measurement of osmolality using a vapor pressure osmometer. 
Afterward, the mice were euthanized in an isoflurane chamber, and blood was collected by 
cardiac puncture for measurement of blood urea nitrogen (BUN) followed by exsanguination and 
removal of the kidneys, as described previously 5. The protocol for use of these mice was 
approved by the Institutional Animal Care and Use Committee at KUMC.  
 
CD-specific knockout of ILK in Pkd1 mutant mice and pcy mice. To study the effect of ILK 
knockdown in PKD, we bred Pkd1fl/fl mice 37 with Ilkfl/fl mice. Ilk fl/+;Pkd1fl/fl mice were crossed 
with Ilkfl/+;Pkd1fl/+;Pkhd1-Cre mice to generate litters of PKD mice (Pkd1fl/fl;Pkhd1-Cre) with 
Ilk+/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/+ PKD), Ilkfl/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/-PKD) and 
Ilkfl/fl;Pkd1fl/fl;Pkhd1-Cre (Ilk-/- PKD) ILK alleles in CD cells. Non-cystic littermate controls 
(Ilk+/+ CD, Ilk+/- CD, Ilk-/- CD) were also generated using this breeding strategy. One group of 
mice was set aside for survival study where food and water were provided ad libitum and mice 
were monitored every day until death or euthanized when there were signs of imminent death, 
including labored breathing and inability to move 227. A second group of mice was assessed at 
PN day 25. These mice were anesthetized, and serum and tissues were harvested as described 
above, and killed by exsanguination. All mice were F3-F5 generations on the C57BL/6 
background. To confirm the results in a slowly progressive model of PKD, we knocked down 
ILK expression in CDs of pcy/pcy (pcy) mice, a model orthologous to human nephronophthisis 
type 3 (NPHP3). Disease progression in pcy mice is similar to ADPKD with kidney enlargement 
to several times normal size and progressive interstitial fibrosis 228. Previously, we showed that 
kidney volume increased exponentially up to 20 weeks of age, after which there was a plateau as 
renal parenchyma was replaced with fibrosis 228. In general, these mice survive to ~40 weeks of 
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age 5. Ilkfl/+ mice and Pkhd1-Cre mice were bred to pcy mice and backcrossed for eight 
generations. These mice were then bred to obtain Ilk+/+;pcy/pcy (Ilk+/+ pcy) and Ilkfl/+;Pkhd1-
Cre;pcy/pcy (Ilk+/- pcy) mice. Since mice with complete loss of ILK died by 10 weeks, Ilk-/- pcy 
mice were not used. In one group, the mice were euthanized for tissue analysis at 10 weeks of 
age, as described above. Mice in the survival study had free access to food and water ad libitum. 
At 25 weeks, 50-100 μl of blood was collected from the tail vein for BUN analysis. These mice 
were monitored for survival as described above.  
 
Genotyping. We used a PCR method for genotyping ILK floxed mice. The forward primer 
sequence was 5′-GTTTCGCGGTGCTTCTGTG-3′, and the reverse sequence was (5′-
AAAAGCCTTTGATCCTTGAATGG-3′). For genotyping wildtype and floxed Pkd1 alleles, the 
forward primer was 5′-CCTGCCTTGCTCTACTTTCC -3′, and the reverse primer was 5′- 
AGGGCTTTTCTTGCTGGTCT -3′. For genotyping for Cre alleles, the forward sequence was 
5′- GCGGTCTGGCAGTAAAAACTATC -3′, and the reverse primer was 5′- 
GTGAAACAGCATTGCTGTCACTT -3′.  
 
Western blot analysis. ADPKD and NHK cells were seeded onto plastic petri dishes (100 mm 
diameter) containing DMEM/F12 medium with 1% FBS. Serum was reduced to 0.002% at 75% 
confluency. Cells were then treated as indicated and lysates were prepared in triton lysis buffer at 
specific time points. Lysates were also prepared from renal tissues as described previously 229. 
Total protein content was determined using BCA protein assay (Pierce, Rockford, IL) and 50 μg 
of protein was used for immunoblot analysis 224. The following antibodies were used P-Akt 
[9271 Cell Signaling Technology, Beverly, MA (CS)], Akt (CS 9272), GAPDH (CS 2118), ILK 
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(EP-1593Y, Origene, Rockville, MD) and sc13075 (Santa Cruz, CA), P-S6K (CS 9234), S6K 
(CS 9292). Following incubation with an HRP-linked secondary antibody against rabbit or 
mouse (NA934, NA931; GE Healthcare), the blots were detected with ECL (RPN2232, GE 
Healthcare), imaged in AI 600 imager and quantified with Biorad Quantity One program.  
 
Histology, immunohistochemistry, and immunofluorescence. Kidney cross sections were fixed in 
4% paraformaldehyde overnight, embedded into paraffin blocks and 5 μm sections were placed 
on glass slides. Immunohistochemical staining for cleaved caspase-3 (CS 4858) was performed 
by the Department of Pathology and Laboratory Medicine core facility at KUMC. For 
quantification of cleaved caspase-3 staining, sections were blinded for the experimental 
condition, and the total number of cleaved caspase-3 stained cells were manually counted and 
normalized to the total non-cystic surface area of the kidney (% cleaved caspase-3). For 
immunofluorescence, tissue slices were deparaffinized, rehydrated and incubated with the 
following primary antibodies: Ki-67 (Abcam [ab] Inc., Cambridge, MA; ab15880) and Ki-67 
blocking peptide (ab15881), ILK (EP-1593Y, Origene), P-S6 (CS 4858) followed by incubation 
with fluorescent conjugated secondary antibody (ab 150084). Sections were co-stained with 
FITC-conjugated DBA (FL-1031; Vector Laboratories, Burlingame, CA) to label CD cells and 
mounted with DAPI (ThermoFisher Scientific P36931). Slides were coded to conceal the group 
assignment and three non-overlapping fields per section were imaged using a Nikon Eclipse Ti 
microscope (Nikon Instruments, Melville, NY). Quantification of nuclear Ki-67 and cytoplasmic 
P-S6 staining was performed with a multi-wavelength cell scoring application in Metamorph 
Image Analysis software (Molecular Devices, Sunnyvale, CA). 
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Measurement of renal cystic area. Tissue sections were stained with hematoxylin and eosin and 
imaged using a dissecting microscope connected to a digital camera (Leica Microsystems, 
Buffalo Grove, IL). Slides were coded, and total number of cysts, cystic area and total area of the 
kidney were measured using Image Pro Premiere (Media Cybernetics Inc, Silverspring, MD) 5. 
 
Measurement of tissue fibrosis. Tissue sections were stained with Masson’s trichrome, causing 
collagen fibers to appear blue 5. Pkd1fl/fl;Pkhd1-Cre mice have aggressive disease and die of 
massively enlarged kidneys, before excessive collagen/ECM deposition. Accordingly, we 
observed only mild collagen deposition within the cortex, whereas there were dramatic pre-
fibrotic edematous areas in the cortex and detectable fibrosis within the medulla. Tissues were 
scored by the naïve observer assigning a percent of cortical area with pre-fibrotic edema and 
collagen deposition per total area of the cortex within the section. We also measured renal 
fibrosis in pcy mice which develop significant renal fibrosis by 10 wk. Percent fibrosis was 
scored based on both pre-fibrotic and fibrotic areas.  
 
Measurement of blood urea nitrogen (BUN). Serum was isolated from blood collected at the time 
of euthanasia by centrifugation at 10,000 RPM for 10 min. Urea concentration was estimated 
using a colorimetric QuantiChrom Urea assay kit (DIUR 500; Bioassay Systems, Hayward, CA) 
and BUN was calculated using the formula BUN = (Urea/2.14).  
 
Statistics. Data are expressed as mean ± standard error (SE). Unless noted otherwise, statistical 
significance was determined by one-way analysis of variance (ANOVA) and Student-Newman-
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Keuls (SNK) post-test for multiple comparisons or unpaired t-test for comparison between 
control and treated groups. For survival studies, the Gehan-Breslow analysis was performed to 
determine statistical significance of the survival curves, and pairwise analysis was performed 
using the Bonferroni Method. 
 
3.4. Results 
3.4.1. Effect of periostin on ILK-mTOR signaling and proliferation of ADPKD cells 
ILK was immunoprecipitated from primary ADPKD and normal human kidney (NHK) 
cells and incubated with GSKα/β protein or myelin basic protein in a kinase assay 185, 200. 
Consistent with previous reports, ILK appeared to be capable of phosphorylating these substrates 
(Figure 3-1); however, it is unclear if other components of the complex were 
immunoprecipitated with ILK 204, 208, 221. Basal ILK activity was higher in ADPKD than NHK 






















Figure 3-1. Effect of periostin on ILK activity in cultured ADPKD cells. (A) Primary ADPKD and 
normal human kidney (NHK) cells were grown to confluency, and then ILK was immunoprecipitated from 
cell lysates using an ILK antibody attached to magnetic beads. ILK activity was determined from the 
phosphorylation of GSK3α/β fusion protein (P-GSK3). Numbers above the bands indicate the kidney 
number in the PKD biospecimen repository. The negative control (NC) represents the level P-GSK3 in a 
kinase assay containing ILK that was immunoprecipitated from ADPKD cells, and all other reagents, 
except ATP. (B) ILK activity was defined as the P-GSK3 band intensity minus the band intensity of the 
NC, divided by the intensity of the total ILK band. N = 8 for NHK cells and N = 6 for ADPKD cells. †P< 
0.05 (C) ADPKD cells were treated with 250 ng/ml periostin from 15 min to 24 h, and ILK activity was 
determined. Baseline activity (control treatment) was set to 100%. ILK activity increased as early as 15 
min and remained elevated for at least 1 h. **P < 0.01, compared to control treated ADPKD cells.  
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Previously, we found that periostin stimulated the proliferation of ADPKD cells, but not 
NHK cells, a difference that may be related to increased expression of αV-integrin in the cystic 
cells 2. Periostin increased phosphorylated Akt (P-Akt/Akt) and S6K (P-S6K/S6K), a target of 
mTOR, in as early as 15 min and levels remained elevated for 24 h (Figure 3-2). Incubation with 
CPD 22, an ILK inhibitor 223, blocked periostin-induced phosphorylation of Akt and S6K 
(Figure 3-3 A, B). Periostin and epidermal growth factor (EGF) increased ADPKD cell 
proliferation to similar levels. Incubation with CPD 22 blocked periostin-induced cell 
proliferation (Figure 3-3 C) but did not affect the EGF response.  
To confirm the results, we used a lentiviral shRNA approach to knock down ILK 
expression in ADPKD cells. In three separate experiments, two ILK shRNA constructs were 
used, achieving 46-54% reduction in ILK expression (Figure 3-4 A). Periostin increased P-
Akt/Akt and P-S6K/S6K to the same level in the absence and presence of scrambled shRNA 
(data not shown). By contrast, ILK knockdown prevented periostin stimulation of the Akt/mTOR 
pathway (Figure 3-4 B, C) and blocked periostin-induced cell proliferation (Figure 3-4 D). In 
contrast to ILK inhibition with CPD 22, disruption of the IPP complex by ILK knockdown 
decreased EGF-induced ADPKD cell proliferation, supporting a role for the IPP complex in 







Figure 3-2. Effect of periostin on the Akt/mTOR pathway in human ADPKD cells. ADPKD cells (N = 
4) were incubated in media containing 250 ng/ml periostin for 15 min, 3 h or 24 h. Levels of (A) 
phosphorylated (P-Akt) and (B) phosphorylated (P-S6K), a downstream target of mTOR, were determined 
by immunoblot analysis. Numbers above representative immunoblots are (A) P-Akt/Akt and (B) P-
S6K/S6K, normalized to control (set to 1.0). Bar graphs represent the mean and standard error (S.E.) for 
(A) P-Akt/Akt and (B) P-S6K/S6K from cell preparations from four different ADPKD kidneys. *P < 0.05, 











Figure 3-3. Effect of ILK inhibition on periostin-induced Akt/ mTOR activation and proliferation of 
ADPKD cells. ADPKD cells were treated with or without 2.5 µM CPD22 for 1 h and then stimulated with 
periostin for 15 min. Numbers above representative immunoblots are (A) P-Akt/Akt and (B) P-S6K/S6K. 
(C) The effect of ILK inhibition on ADPKD proliferation was determined by treating cells with either 250 
ng/ml periostin or 25 ng/ml epidermal growth factor (EGF) for 48 h in the presence or absence of 1 µM 
CPD 22. Cell numbers were counted using BioRad TC20 cell counter. *P < 0.05 and **P< 0.01, compared 
to control and #P < 0.05, ##P <0.01, compared to periostin alone.  
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Figure 3-4. Effect of ILK knockdown on periostin-induced Akt/mTOR signaling and ADPKD cell 
proliferation. To confirm the role of ILK, ADPKD cells were infected with lentivirus containing shRNA 
against ILK or a non-specific (scrambled) sequence. (A) Representative immunoblot of ILK in ADPKD 
cells after infection by lentiviral ILK shRNA (ILK shRNA 1 or ILK shRNA 2) or a non-specific 
(Scrambled) sequence. Numbers below the bands indicate the percentage of ILK, relative to scrambled 
shRNA cells. Cells were treated with 250 ng/ml periostin for 15 min and levels of (B) P-Akt/Akt and (C) 
P-S6K/S6 were measured by immunoblot analysis. Summary data for (D) P-Akt/Akt and (E) P-S6K/S6K 
were normalized to basal conditions of scrambled shRNA cells (set to 1.0). (D) ADPKD cells were 
infected with an ILK (shRNA 1 or shRNA 2) or a scrambled shRNA lentivirus, and then treated with 
periostin or 100 ng/ml EGF for 24 h. Cell proliferation was measured by Promega MTT assay and 
normalized to basal proliferation of cells infected with the scrambled shRNA (set to 100%). *P < 0.05, **P 
< 0.01 and ***P < 0.001, compared to control or basal conditions of scrambled shRNA infected cells. 
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3.4.2. Generation of mice with CD-specific deletion of ILK 
Ilk fl/fl mice 225 were crossed with Pkhd1-Cre mice 226 to generate wild type (WT: Ilk+/+ 
CD), Ilkfl/+;Pkhd1-Cre (Ilk+/- CD) and Ilkfl/fl;Pkhd1-Cre (Ilk-/- CD) mice. ILK deletion in CDs was 
confirmed by co-immunofluorescence using an ILK antibody and Dolichos biflorus agglutinin 
(DBA, green) (Figure 3-5).  
Ilk-/- CD mice had lower body weight (BW) and developed a urine concentrating defect 
(Table 3-1), consistent with a previous report 232. Kidneys of Ilk-/- CD mice had caspase-3-
mediated anoikis 10 with apoptotic cells in the lumen and dilated cortical tubules (Figure 3-6). 
There was a significant increase in blood urea nitrogen (BUN) as early as 25 days. By 10 weeks 
of age, Ilk-/- CD mice had reduced kidney size (Table 3-1), massive levels of apoptosis and renal 
fibrosis, and the mice died by 10.4 ± 0.34 weeks (N = 14). By contrast, Ilk+/- CD mice had 







Figure 3-5. Collecting-duct specific ILK knockout in mice. At postnatal (PN) day 25, Ilk+/+;Pkhd1-Cre 
(Ilk+/+ CD) and Ilkfl/fl;Pkhd1-Cre (Ilk-/- CD) mice were euthanized, and kidney sections were stained for 
ILK (red), Dolichos biflorus agglutinin (DBA, green) and DAPI nuclear stain (blue). Left panels (A, C) are 
images of kidney sections that were stained for ILK expression (red). Right panels (B, D) are merged 
images in which ILK, DBA, and DAPI staining was superimposed. Top panels (A, B) show an Ilk+/+ CD 
mouse kidney section with normal ILK expression in a collecting duct (arrow). Bottom panels (C, D) show 











Table 3-1. Effect of collecting duct (CD)-specific knockout of ILK on body weight, kidney weight, 
and urine concentrating ability. Body and kidney weights and urine concentrating ability were 
determined at 25 days and 10 weeks of age for wild type ILK (Ilk+/+ CD), Ilkfl/+;Pkhd1-Cre (Ilk+/- CD) and 
Ilkfl/fl;Pkhd1-Cre (Ilk -/- CD) mice. To evaluate urine concentrating ability, drinking water was removed for 
3 h, spot urine was collected, and urine osmolality (OsM, mosmoles/kg water) was measured using a vapor 
pressure osmometer. Ilk-/- CD mice had decreased body weight (BW) and lower urine osmolality (OsM, 
mosmoles/kg) compared to Ilk+/+ CD and Ilk+/- CD mice, confirming that ILK ablation leads to a defect in 













Figure 3-6. Effect of collecting duct-specific ILK deletion. Kidney sections from wild type ILK (Ilk+/+ 
CD;A, D, G), Ilkfl/+;Pkhd1-Cre (Ilk+/- CD;B, E, H) and Ilkfl/fl;Pkhd1-Cre (Ilk-/- CD;C, F) mice at 25 days 
(A, B, C), and 10 (D, E, F) and 51 weeks (G, H) were stained with hematoxylin and eosin. All images are 
the same magnification. Scale bar = 50 µm. (I) Tissue sections were stained for cleaved caspase-3 to 
determine if the cellular loss of ILK caused apoptosis/anoikis10. The number of cleaved caspase-3 positive 
cells in the kidney sections were counted and represented as a percentage of non-cystic surface area (% 
cleaved caspase-3). (J) Blood collected from mice at postnatal day 25 (PN 25) and 10 wk, were analyzed 
for blood urea nitrogen (BUN). 
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3.4.3. Effect of ILK on cystic disease progression in ADPKD mice 
ILK expression was knocked down in CDs of Pkd1fl/fl;Pkhd1-Cre (PKD) mice, an 
orthologous ADPKD model with aggressive disease 226. These mice typically die by 33 days 
with massively enlarged kidneys. We generated Ilk+/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/+ PKD), 
Ilkfl/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/-PKD) and Ilkfl/fl;Pkd1fl/fl;Pkhd1-Cre (Ilk-/- PKD) mice (Figure 4). 
By 25 days, the PKD mice had massively enlarged kidneys (Figure 3-7 A, B) with percent 
kidney weight (KW) to BW equaling 18.0% (Figure 3-7 D), compared to 1.3% for WT mice 
(Table 3-1). Loss of one or both alleles of ILK reduced KW(%BW) to 12.7% or 5.1%, 
respectively. There was no difference in BW among the three genotypes. Cystic area of the 
kidneys was reduced from 55% in Ilk+/+ PKD mice to 43% and 28% in Ilk+/- PKD and Ilk-/- PKD 
mice, respectively (Figure 3-7 B, E). There were also fewer cysts in Ilk+/- PKD and Ilk-/- PKD 
kidneys; however, this difference was not significant (data not shown).  
To determine if CD-specific knockdown of ILK decreased cell proliferation, the number 
of Ki-67 positive cells in DBA-positive tubules was determined using immunofluorescence 
(Figure 3-8). We found that Ki-67 positive cells were dramatically decreased with the loss of 



















Figure 3-7. Effect of ILK expression on cyst growth in PKD mice. Representative images of (A) 
kidneys and (B) kidney sections from Ilk+/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/+ PKD), Ilkfl/+;Pkd1fl/fl;Pkhd1-Cre 
(Ilk+/-PKD) and Ilkfl/fl;Pkd1fl/fl;Pkhd1-Cre (Ilk-/- PKD) and wild type (WT) mice demonstrate that the loss of 
ILK expression in CD cells reduced cyst growth in PKD mice. All images were taken at the same 
magnification. Scale Bar = 1 mm. Bar graphs are mean ± S.E. for (C) Body weight and (D) kidney weight 
as a percentage of body weight (%BW) for N = 10 mice per group. (E) Cystic index is represented as the 
percentage of cystic area per total kidney cross-sectional surface area for N = 7 mice per group. **P < 0.01 









Figure 3-8. Effect of ILK expression on renal cell proliferation in PKD mice. Representative kidney 
sections from (A) wild type, WT, (B) Ilk+/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/+ PKD), (C) Ilkfl/+;Pkd1fl/fl;Pkhd1-Cre 
(Ilk+/-PKD) and (D) Ilkfl/fl;Pkd1fl/fl;Pkhd1-Cre (Ilk-/- PKD) mice were stained with an antibody to Ki-67, a 
marker for cell proliferation (red). Tissues were also stained for DBA (green) to detect collecting ducts 
(CD) and the DAPI nuclear stain (blue). Arrows indicate Ki-67 positive CD cells. Scale bar = 5 µm. (E) 
Summary for the number of cells positive for nuclear Ki-67, normalized to the total nuclei in DBA-positive 
positive CD. Data are mean ± S.E. for kidneys from three mice per group. **P<0.01 compared to WT, #P 
<0.05 and ##P <0.01 compared to Ilk+/+ PKD. 
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Pkd1fl/fl;Pkhd1-Cre kidneys had higher P-Akt/Akt levels than WT kidneys 154, 215 and 
partial loss or complete ablation of ILK reduced P-Akt/Akt (Figure 3-9 A, F). Percentage of CD 
cells with phosphorylated S6 (P-S6) was higher in Ilk+/+ PKD compared to WT mice, and partial 
or complete loss of ILK significantly diminished P-S6 in CD-derived cysts (Figure 3-9 B-E, G). 
These data support the hypothesis that ILK is a key regulator of Akt/mTOR signaling in PKD.  
To determine the effect of ILK on RTK signaling, we examined levels of ERK activity 
(P-ERK/ERK) (Figure 3-10). Ilk+/+ PKD kidneys showed a significant increase in ERK activity 
compared to WT 93. Loss of one allele of ILK decreased P-ERK; however, this was not 
significant. By contrast, ILK ablation in Ilk-/- PKD kidneys significantly reduced P-ERK. We 
think that disruption of IPP complex due to loss of ILK also affects RTK signaling 192, 230, 231  
There was an increase in cleaved caspase-3-positive nuclei in PKD kidneys (Figure 
3-11). Complete loss of ILK further increased the number of apoptotic cells and caused CD cells 
to be shed into the lumen. Previously, loss of cystic cells due to apoptosis was shown to reduce 




















Figure 3-9. Effect of ILK expression on Akt/mTOR signaling in PKD kidneys. (A) Immunoblot 
analysis was used to compare phosphorylated levels of renal Akt (P-Akt) in Ilk+/+;Pkd1fl/fl;Pkhd1-Cre 
(Ilk+/+ PKD), Ilkfl/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/- PKD), Ilkfl/fl;Pkd1fl/fl;Pkhd1-Cre (Ilk-/- PKD) and wildtype 
(WT) mice. Representative sections from (B) WT, (C) Ilk+/+ PKD, (D) Ilk+/-PKD and (E) Ilk-/- PKD mice 
were stained with an antibody to P-S6 (red). Tissues were also stained for DBA (green) to detect collecting 
ducts (CD) and the DAPI nuclear stain (blue). Arrows indicate cytoplasmic P-S6 in CD cells. All images 
were taken at the same magnification. Scale bar = 5 µm. (F) Summary of the effect of CD-specific ILK 
expression on renal P-Akt/Akt levels. (G) Percentage of cytosolic P-S6 positive cells, normalized to the 
total nuclei in DBA-positive collecting ducts. Data are mean ± S.E. for kidneys from three mice per group. 








Figure 3-10. Effect of ILK expression on renal P-ERK levels in PKD mice. Immunoblot analysis was 
used to compare phosphorylated levels of renal ERK (P-ERK) in Ilk+/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/+ PKD), 
Ilkfl/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/- PKD), Ilkfl/fl;Pkd1fl/fl;Pkhd1-Cre (Ilk-/- PKD) and wildtype (WT) mice. Each 
lane represents a single mouse kidney lysate (N = 3 per group). Summary of the effect of CD-specific ILK 
expression on renal P-ERK/ERK levels. Data are means ± S.E. for kidneys from three mice per group †P= 
0.05, compared to WT. #P <0.05, compared to Ilk+/+ PKD. 
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Figure 3-11. Effect of ILK expression on caspase-3-mediated apoptosis in PKD mice. Representative 
kidney sections from (A) wild type, WT, (B) Ilk+/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/+ PKD), (C) 
Ilkfl/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/-PKD) and (D) Ilkfl/fl;Pkd1fl/fl;Pkhd1-Cre (Ilk-/- PKD) mice were stained with 
an antibody to cleaved caspase-3 to visualize apoptotic cells (brown staining; arrows). All images were 
taken at the same magnification. Scale bar = 50 µm. (E) Total number of cleaved caspase-3 positive cells 
in the entire section was counted and normalized to the non-cystic surface area of the kidney (represented 
as % cleaved caspase). Data are means ± S.E. for kidneys from three mice per group. *P<0.05 compared to 
WT, ###P <0.001 compared to Ilk+/+ PKD. 
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3.4.4. Effect of ILK on interstitial fibrosis, renal function and survival in PKD kidneys 
Pkd1fl/fl;Pkhd1-Cre mice develop extensive interstitial damage involving fibrosis and 
edema, a precursor for collagen deposition and fibrosis. At PN day 25, there was massive 
fibrosis/edema in Ilk+/+ PKD kidneys with 91% of the interstitial space showing pathologic 
damage (Figure 3-12). Ilk+/+ PKD mice showed a marked increase in BUN (132.8±7.7 mg/dl; 
normal range is 8-33 mg/dl). Loss of one or both alleles of ILK in CD cells caused a reduction in 
fibrosis. Decreased expression of ILK in Ilk+/-PKD mice reduced BUN levels, compared to Ilk+/+ 
PKD mice. By contrast, BUN levels of Ilk -/- PKD mice were similar to Ilk+/+ PKD mice, 
suggesting that renal injury due to loss of ILK confounds the improved cystic phenotype. 
Next, we determined if knockdown of ILK alters the lifespan of the PKD mice. 
Pkd1fl/fl;Pkhd1-Cre mice expressing normal ILK lived to ~33 days (Figure 3-13). PKD mice 
heterozygous at the ILK locus (Ilk+/- PKD) survived to 42 days, displaying a 27% increase in 
lifespan. Complete ILK knockout increased survival to 40 days; however, this was not 
significant. These data indicate that a reduction in ILK decreased cyst growth by inhibiting 
mitogenic pathways, leading to improved renal function and survival. By contrast, complete loss 






Figure 3-12. Effect of ILK expression on interstitial fibrosis and renal function in PKD mice. 
Representative kidney sections from (A) wild type (WT), (B) Ilk+/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/+ PKD), (C) 
Ilkfl/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/-PKD) and (D) Ilkfl/fl;Pkd1fl/fl;Pkhd1-Cre (Ilk-/- PKD) mice were stained with 
Masson trichrome to visualize pathogenic collagen deposition (stained blue). All images were taken at the 
same magnification. Scale bar = 50 µm. (E) Tissue sections were coded to conceal the group assignment 
prior to being visually scored for percentage of interstitial fibrosis and edema per total area of the tissue 
section Data are means ± S.E. for kidneys from seven mice per group. (F) Serum was isolated from WT (N 
= 5), Ilk+/+ PKD (N = 10), Ilk+/- PKD (N = 10), Ilk-/- PKD (N = 7) and blood urea nitrogen (BUN) was 




Figure 3-13. Effect of ILK expression on survival of PKD mice. (A) Kaplan-Meier survival curve for 
Ilk+/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/+ PKD, N = 11), Ilkfl/+;Pkd1fl/fl;Pkhd1-Cre (Ilk+/-PKD, N = 13) and 
Ilkfl/fl;Pkd1fl/fl;Pkhd1-Cre (Ilk-/- PKD, N = 8) mice. The dotted line represents the time point at which 50% 
of the mice had died. ILK knockdown in CD cells extended the survival of PKD mice. (B) Heterozygous 
loss of ILK significantly increased mean survival age from 33 ± 2 for the Ilk+/+ PKD mice to 42 ± 2 days 
for the Ilk+/- PKD mice, *P< 0.05. Complete loss of ILK (Ilk -/- PKD) appeared to extend survival; however, 
the difference did not reach statistical significance. 
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3.4.5. Effect of ILK on PKD progression in pcy/pcy mice 
Next, we examined the role of ILK in pcy/pcy (pcy) mice, a well-characterized slowly 
progressive model of PKD 235, 236. We crossed Ilk fl/+ and Pkhd1-Cre mice to pcy mice to 
generate Ilk+/+;pcy/pcy (Ilk+/+ pcy) and Ilkfl/+;Pkhd1-Cre;pcy/pcy (Ilk+/- pcy) mice. Male Ilk+/+ pcy 
and Ilk+/- pcy mice were euthanized at 10 weeks, and BW, KW(%BW), cystic index and fibrosis 
were measured (Figure 3-14). We found that Ilk+/- pcy mice had a pronounced reduction in 
KW(%BW), with no effect on body weight. There was a pronounced reduction in cystic area and 
cyst number compared to Ilk+/+ pcy mice. Measurement of Ki-67 positive cells showed a 59% 
reduction in proliferating cells in the Ilk+/- pcy kidneys. There was prominent interstitial fibrosis 
in pcy mice, and reduced ILK decreased fibrotic area by more than 50%. mTOR signaling is 
elevated in pcy kidneys 4 and reduced ILK expression downregulated both P-S6K and total S6K 
(Figure 3-15). We found that the average BUN for Ilk+/+ pcy mice at 25 weeks was 57.4 mg/dl, 
demonstrating a decline in renal function (Figure 3-16 A). These mice lived to an average age of 
40 weeks (Figure 3-16 B) 5. By comparison, BUN for Ilk+/- pcy littermates was significantly 
lower (42.0 mg/dl) and the mice survived to 48 weeks, indicating a 20% increase in lifespan. 
Taken together, these data demonstrate that ILK plays an important role in renal cyst growth and 



















Figure 3-14. Effect of ILK expression on renal cyst development in pcy mice. (A) Representative images 
of kidney cross-sections of Ilk+/+;pcy/pcy (Ilk+/+ pcy) and Ilkfl/+;Pkhd1-Cre;pcy/pcy (Ilk+/- pcy) mice at 10 
weeks of age. Images were taken at the same magnification. Scale Bar = 1 mm. There was a dramatic 
reduction in (B) kidney weight (% BW), (C) cystic index in Ilk+/-pcy mice compared to Ilk+/+ pcy mice. 
compared to Ilk+/+ pcy mice. Proliferating cells were determined in kidney sections from (D) Ilk+/+ pcy and 
(E) Ilk+/- pcy mice that were stained for Ki-67 (red), DBA (green) and DAPI (blue). Arrows indicate Ki-67 
positive cells. Images were taken at the same magnification. Scale bar = 5 µm. (F) Comparison of nuclear Ki-
67 staining in Ilk+/+ pcy and Ilk+/- pcy sections, normalized to total nuclei. Representative kidney sections 
from (G) Ilk+/+ pcy and (H) Ilk+/- pcy mice were stained with Masson’s trichrome to visualize interstitial 
fibrosis. Scale bar = 50 µm. (I) Tissue sections stained with Masson’s trichrome were coded to conceal the 
group assignment and visually scored for percentage of interstitial edema and fibrosis. *P <0.05, **P <0.01, 































































Figure 3-15. Effect of ILK expression on renal mTOR signaling in pcy kidneys. (A) Immunoblot 
analysis was used to compare phosphorylated S6 kinase (P-S6K) and total S6K in kidneys of 10-week old 
Ilk+/+;pcy/pcy (Ilk+/+), and Ilkfl/+;Pkhd1-Cre;pcy/pcy (Ilk+/-) mice. P-S6K and S6K were normalized to 
GAPDH, a reference protein. The bar graphs are mean ± SE for the effect of ILK expression on renal (B) 
P-S6K and (C) total S6K, normalized to GAPDH (N = 4 per group). Previously, total S6K and P-S6K were 
shown to be upregulated in pcy mice, relative to total protein4. These data show that reduced ILK 
expression in CDs of pcy mice significantly reduced P-S6K and total S6K, demonstrating that ILK is 


















Figure 3-16. Effect of ILK knockdown on renal function and survival in pcy mice. Ilk+/+;pcy/pcy 
(Ilk+/+ pcy) and Ilkfl/+;Pkhd1-Cre;pcy/pcy (Ilk+/- pcy) mice were given standard chow and water ad libitum 
and monitored regularly until moribund. (A) At 25 weeks, blood was collected from the tail vein and BUN 
was measured to assess renal function (N = 12 mice per group). **P <0.01, compared to Ilk+/+ pcy. (B) 
Kaplan-Meier survival curve indicates that heterozygous loss of ILK significantly increased the average 
lifespan of the pcy mice (N = 14 mice per group). Average survival age increased from 40 ± 2 weeks for 
the Ilk+/+ pcy mice to 48 ± 2 weeks for the Ilk+/- pcy mice, P < 0.001. 
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3.5. Discussion  
Our results demonstrate that 1) ILK is a central intermediate for periostin activation of 
the Akt/mTOR pathway and proliferation of human ADPKD cells, 2) pharmacological inhibition 
of ILK blocked periostin-induced Akt/mTOR signaling and cell proliferation, 3) heterozygous 
knockdown of ILK in CDs of WT mice had no effect on renal morphology or function, whereas 
complete ILK knockout caused caspase-3-mediated anoikis, dilated cortical tubules with 
apoptotic cells in the lumens, interstitial fibrosis, and death of the mice by 10 weeks of age, 4) 
reduced ILK expression in Pkd1fl/fl;Pkhd1-Cre and pcy/pcy mice decreased renal Akt/mTOR 
activity, cell proliferation, cyst growth, and interstitial fibrosis and significantly extended the 
survival of PKD mice and 5) homozygous deletion of ILK in the CDs of Pkd1fl/fl;Pkhd1-Cre 
mice decreased cystic index, in part, due to apoptosis of the cystic cells.  
 In PKD, aberrant cell proliferation is responsible for the formation and growth of renal 
cysts; however, the mechanisms remain unclear. One hypothesis is that mutations in the PKD 
genes incite a maladaptive repair mechanism, involving pathways that activate cell proliferation 
106. Abnormal and extensive expression of ECM molecules, including laminins, collagens, and 
matricellular proteins, accelerate cyst growth through activation of integrin signaling 2, 23, 118, 143, 
155. Recently, we discovered that periostin, a tissue repair molecule, was highly overexpressed in 
ADPKD, ARPKD and animal models of cystic disease 2. Periostin binding to αV-integrins 
activates mTOR and promotes the proliferation of human ADPKD cells. Global knockout of 
periostin in pcy mice led to a striking reduction in renal mTOR activity, cell proliferation, cystic 
area and tubulointerstitial fibrosis 5.  
ECM and matricellular proteins regulate gene expression by integrin signaling through 
ILK, which has been shown to be necessary for embryonic development of the kidneys. Deletion 
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of ILK in the ureteric bud of Ilkfl/fl;HoxB7-Cre mice caused tubule obstruction, and the mice died 
at 8 weeks of age 211. Conditional knockout of ILK using a tamoxifen-inducible Cre caused a 
urinary concentrating defect which the authors attribute to a disruption of AQP2 expression and 
localization; however, a compensatory increase in V2 receptor activation or cAMP expression 
was not observed. Morphological changes in the kidneys were not reported 232. Here, we show 
that postnatal ablation of ILK in CDs caused a urinary concentrating defect, a decline in body 
weight and the mice died by 10 weeks of age. Loss of ILK caused anoikis and tubule dilations in 
the kidneys. Thus, complete knockout of ILK appeared to disrupt the connection between the 
ECM and cell cytoskeleton, leading to detachment of CD cells into the lumen and tubule 
obstruction.  
Pkd1fl/fl;Pkhd1-Cre mice die at ~33 days of age due to renal failure. Complete knockout 
of ILK caused apoptosis of the cystic epithelial cells, contributing to a reduction in the cyst area 
and size of the cystic kidneys. Mice with heterozygous knockout of ILK in CDs had normal 
kidneys, urinary concentrating ability, BUN and lived beyond one year. Importantly, reduction in 
ILK expression in the Pkd1fl/fl;Pkhd1-Cre mice and pcy mice decreased Akt/mTOR signaling, 
cell proliferation, cyst number, cystic index and fibrosis. There was improved renal function and 
increased lifespan of the PKD mice. Previously, a small molecule ILK inhibitor was shown to 
reduce renal fibrosis in a model of obstructive nephropathy 237, suggesting that ILK inhibition 
may be an effective approach for the treatment of ADPKD. Since complete knockout of ILK in 
CD cells caused renal injury, long-term use of an ILK inhibitor would need to be considered with 
caution. 
In summary, aberrant secretion of periostin by cystic epithelial cells activates the ILK-
Akt-mTOR pathway, promoting cyst growth and fibrosis (Figure 3-17). We propose that 
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targeting the periostin-integrin-ILK axis may be a potential therapeutic approach to slow cyst 














Figure 3-17. ILK promotes periostin-induced ADPKD cell proliferation and cyst growth. Binding of 
periostin to αV-integrins stimulates integrin-linked kinase (ILK), a scaffold protein that is essential for 
linking the extracellular matrix to the actin cytoskeleton, leading to Akt/mTOR pathway-mediated cell 
proliferation and cyst growth in ADPKD. 
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CHAPTER 4. PERIOSTIN ACTIVATES PATHWAYS INVOLVED IN TISSUE REPAIR 
AND ACCELERATES PKD PROGRESSION 
4.1. Abstract 
In polycystic kidney disease (PKD), persistent activation of the Akt/mTOR pathway, cell 
proliferation and matrix production by cystic epithelial cells appears to be consistent with the 
activation of a futile repair response that contributes to cyst growth and tubulointerstitial fibrosis. 
Periostin is a matricellular protein involved in tissue repair and is aberrantly expressed in PKD. 
Previously, we showed that periostin binds to αVβ3- and αVβ5-integrins and activates integrin-
linked kinase (ILK) leading to Akt/mTOR-mediated ADPKD cell proliferation. Here, we found 
that periostin activates focal adhesion kinase, Rho GTPase, cytoskeletal reorganization, actin 
stress fiber formation, and cell migration. Periostin also stimulates the expression of genes 
involved integrin signaling and ECM production in human PKD cells. These in vitro data are 
consistent with periostin activation of cellular pathways involved in tissue repair. To determine if 
overexpression of periostin in the cyst-lining cells accelerates PKD progression, we generated 
pcy/pcy mice with conditional overexpression of periostin selectively in collecting duct (CD) 
cells. CD-specific periostin overexpression significantly increased renal mTOR activity, cell 
proliferation, cyst growth and interstitial fibrosis. Taken together, our results suggest that 
aberrant expression of periostin could contribute to a futile repair program, leading to increased 





Autosomal dominant polycystic kidney disease (ADPKD) is a commonly inherited renal 
disorder 238. In ADPKD, renal cyst formation begins in utero and is caused by the aberrant 
proliferation of tubular epithelial cells and accumulation of fluid in the newly formed cysts due 
to transepithelial fluid secretion 76, 79. Several signaling pathways aberrantly regulated in 
ADPKD, have been shown to play a role in cyst growth 116-118, 239. This altered regulation appears 
consistent with transcriptional reprogramming typically seen during tissue repair and perhaps, 
further accelerates the disease 240, 241.  
Periostin, 90-kDa matricellular protein, is typically expressed in tissues involved in 
mechanical stress, such as periodontal ligaments, periosteum, skin, and bone. Atypical 
expression of periostin is also observed in carcinomas, and in the ECM of tissues following acute 
injury to tissues such as the heart, lung and skin 135, 157, 158, 242-244. In addition to modulating 
biomechanical properties of tissues, periostin binds αV-integrins on the cell surface and activates 
cellular pathways involved in cell proliferation, survival, and profibrotic TGF-β signaling 2, 8, 137, 
164, 169-171. 
We found that periostin is aberrantly expressed in human ADPKD, human autosomal 
recessive PKD (ARPKD) and several mouse models of renal cystic disease, while it is not 
expressed in a normal adult kidney 2, 5. Periostin binding to αVβ3- and αVβ5-integrins promotes 
ADPKD cell proliferation by activating integrin-linked kinase (ILK) and stimulating downstream 
Akt/mTOR signaling 245. Further, genetic deletion of periostin in pcy/pcy (pcy) mice decreased 
renal mTOR activity and delayed the progression of the cystic disease, demonstrating that 
periostin is an important modifier of PKD 5. Several human and murine renal injury models 
including, diabetic nephropathy, hypertensive nephropathy, and glomerulosclerosis show 
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aberrant periostin expression. In fact, urinary periostin may be a potential biomarker for chronic 
kidney diseases 136, 243, 244, 246, suggesting that unchecked periostin-integrin signaling may be 
involved in tissue repair in renal pathologies. 
Here, we determined if periostin stimulates pathways involved in tissue repair in human 
ADPKD cells and if overexpression of periostin activates mTOR signaling, promoting 
proliferation and cyst growth, and fibrosis in PKD mice.  
 
4.3. Materials and Methods 
Human ADPKD and normal human kidney cells. Primary cultures of ADPKD and normal human 
kidneys (NHK) cells were generated by the PKD Biomarkers and Biomaterials Core in the 
Kansas PKD Center at the Kansas University Medical Center (KUMC) as described 245. Cells 
were grown in DMEM/F12 supplemented with 5% FBS, penicillin G and streptomycin (P/S), 
and a cocktail of insulin, transferrin, and sodium selenite (ITS). Upon reaching 70-80% 
confluence, the cells were trypsinized using a trypsin-EDTA solution (Sigma Chemical, Saint 
Louis, MO) and re-plated for experiments. Primary ADPKD and NHK cells were not passaged 
more than two times before use in experiments. We tested the effect of 75 kDa (Biovendor, 
Asheville, NC) and full-length 91.7 kDa (R&D Systems, Minneapolis, MN) periostin and found 
that had similar effects on in vitro experiments, consistent with our earlier findings 2, 245, and 
have been used interchangeably.  
 
Cell migration assay. ADPKD cells (1 × 105) were seeded into individual wells of 12-well plates 
containing DMEM/F12, ITS, 1% FBS and P/S. After cells reach approximately 80% confluency, 
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the serum was reduced to 0.05%. 24 h later, a 200 µm pipette tip was used to create a uniform 
scratch in the cell layer near the middle of the well. Immediately after the scratch, cells were 
treated with control media, 250 ng/ml human recombinant periostin or 25 ng/ml hepatocyte 
growth factor (HGF; Sigma Chemical), which was used as a positive control for cell migration 
247. The scratched area was imaged using Nikon Eclipse Ti microscope (Nikon Instruments, 
Melville, NY) with a motorized stage that was controlled by computer software. This allowed 
repeated measurements to be made at the same location within each well. Plates were allowed to 
equilibrate for 4 h in the incubation after setting up the imaging parameters, and images were 
captured for measurements 4 h and 8 h post-wounding. The extent of closure was determined 
relative to the area of the initial wound, using Metamorph Image Analysis software (Molecular 
Devices, Sunnyvale, CA). Percent closure for each treatment was determined from 4 h to 8 h and 
normalized to control. Treatments were carried out in triplicates, and two picture fields per well 
were examined.  
 
Quantitative RT-PCR. NHK and ADPKD cells (0.5 × 106) were plated on transwells (Costar, 
Kennebunk, ME; 34320) and grown in media containing 1% FBS until they formed tight 
epithelial monolayers. Control media or media containing periostin (250 ng/ml) was added to the 
both sides of the monolayer for 24 hours. RNA was isolated using RNeasy isolation kit (Qiagen), 
and its integrity was verified using an Agilent Bioanalyzer (Santa Clara, CA). cDNA was 
synthesized from 1 µg of total RNA, using the iScript™ advanced cDNA synthesis kit for RT-
qPCR (Biorad, Munich, Germany) according to manufacturer instructions. Real-time PCR 
reactions were set up by preparing a master mix of cDNA samples (1.92 µg/ 96-well plate) and 
the SsoAdvanced™ Universal SYBR® Green Supermix (Biorad; 960 µl/ 96-well plate). We 
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used the Biorad PrimePCR array plates for integrin outside-in signaling, collagen diseases, 
wounds and injuries, and transcription factors (tier 1) to screen 220 genes, many of which are 
markers for tissue repair. GAPDH, HPRT1, and TBP were used as reference genes, and results 
were analyzed with the PrimePCR™ Analysis Software (Biorad). Changes greater than 1.5-fold 
and p < 0.05 were considered significant. Three different cell preps were used for the screen, and 
results were validated by qPCR in a separate study with primers purchased from SuperArray 
(Frederick, MD) or Genecopoeia (Rockville, MD).  
 
Measurement of activated Rho. ADPKD and NHK cells were plated onto plastic petri dishes 
(100 mm diameter) and grown in media containing 1% FBS. Serum was reduced to 0.002% 
when the cells reached 75% confluency. Treatments were carried out as indicated, and lysates 
were prepared in Triton lysis buffer at the specified time points. Rho was immunoprecipitated 
from cell lysates using GST-RBD beads that have a high affinity for GTP-bound Rho. For 
negative control, GDP was loaded before immunoprecipitation to inactivate endogenous Rho. 
The immunoprecipitate and the whole cell lysates were immunoblotted using a Rho antibody. 
Rho activity was defined as GTP-bound Rho to total Rho, normalized to control treatment.  
 
Western blot analysis. ADPKD and NHK cells were plated on petri dishes or transwell supports, 
in DMEM/F12 medium as described above. Treatments were as indicated and lysates were 
prepared in Triton lysis buffer at the specified time points. Tissue lysates were also prepared 
from mice kidneys as described previously 229. Total protein concentration was determined using 
BCA protein assay (Pierce, Rockford, IL) and 75 μg of protein was used for immunoblot 
analysis 224. The following antibodies were used: P-FAK (Cell Signaling Technology, Beverly, 
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MA [CS]; 3283), FAK (ThermoFisher Scientific, AHO0502), GAPDH (CS 2118), integrin β1 
(Abcam [ab] Inc., Cambridge, MA; 529751), integrin αv (ab 179475), integrin β3 (CS 4702), and 
periostin (ab 14041). The blots were then incubated with an HRP-linked secondary antibody 
against rabbit or mouse (NA934, NA931; GE Healthcare). Bands were detected with ECL 
(RPN2232, GE Healthcare), imaged using an AI 600 imager (GE Healthcare) and quantified 
with Biorad Quantity One program.  
 
Generation of transgenic mice with conditional overexpression of periostin. A cDNA encoding 
mouse Postn and a 3’ bovine growth hormone polyadenylation signal were subcloned into 
pBT378-mCherry-LSL-MCS. An attB-flanked targeting construct was co-injected with RNA 
encoding the PhiC31 integrase (Applied Stem Cell, Milpitas, CA) into pronuclei of homozygous 
Rosa26-P3 mice 248 by the University of Kansas Medical Center Transgenic and Gene-Targeting 
Institutional Facility. Embryos were implanted in pseudopregnant females and the pups were 
genotyped by PCR to identify a founder with the transgene integrated into the attP sites at the 
Rosa26 locus via PhiC31 mediated integration. This founder line was expanded for further 
analysis. The resulting transgenic strain (Postntg) harbors the Postn coding sequences 
downstream of a splice acceptor and loxP-flanked-mCherry STOP cassette under the 
transcriptional control of the endogenous Rosa26 transcriptional regulatory elements (Figure 
4-6). In the absence of Cre recombinase expression, mCherry (but not Postn) is expressed under 
the control of the broadly expressed Rosa26 promoter. Cre-mediated excision of the floxed-
mCherry STOP results in Postn expression under the transcriptional control of Rosa26. 
Characterization of mice with collecting duct-specific overexpression of periostin. Postntg mice 
were crossed to Pkhd1-Cre mice, which express cre-recombinase specifically in the collecting 
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ducts (CD 226 to generate Postntg;Pkhd1-Cre (PostnTG) and littermates that lacked the cre 
(Postntg) or the transgene (Pkhd1-Cre). Both genotypes will be referred to as wild type (WT) 
since appeared normal and were indistinguishable from each other. To determine the effect of 
CD-specific overexpression of periostin in PKD, we crossed Postntg mice to pcy/pcy (pcy) mice, 
a slowly progressive PKD model 5, 228 , orthologous to human nephronophthisis type 3 (NPHP3). 
The course of disease progression in pcy mice phenocopies human ADPKD, with cystic 
enlargement of the kidney, interstitial fibrosis, and progressive decline in renal function by 48 
weeks of age 228. We generated Postntg;Pkhd1-Cre;pcy/pcy (PostnTG pcy) and littermate 
Postntg;pcy/pcy or Pkhd1-Cre;pcy/pcy mice (both genotypes were indistinguishable and will be 
referred to as pcy mice). We observed normal Mendelian inheritance. Mice were monitored daily 
and provided food and water ad libitum. One group of mice were euthanized at 10 wk of age and 
cardiac puncture was performed to collect blood for measurement of blood urea nitrogen (BUN) 
followed by removal of the kidneys, as described previously 245. The second group of mice was 
euthanized at 30 wk. The third group of mice was set aside for survival study where they 
received food and water ad libitum and were monitored every day until their death. In some 
cases, these mice were euthanized when they showed signs of imminent death, as described 
previously 245. The Animal Care and Use Committee at KUMC approved the protocols for the 
use of these mice. All the mice used for breeding and experiments were 5-6 generations 
backcrossed to pcy/pcy mice.  
 
Genotyping. We genotyped for the presence of the Postntg using PCR. The forward primer 
sequence was 5′- GCCATCATCAAGGAGTTCATGCGCTTC -3′ and the reverse sequence was 
5′- GGAGGTGATGTCCAACTTGATGTTGACG -3′. For genotyping for Cre alleles, the 
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forward sequence was 5′- GCGGTCTGGCAGTAAAAACTATC -3′ and the reverse primer was 
5′- GTGAAACAGCATTGCTGTCACTT -3′. Cre-mediated excision of the floxed-mCherry 
STOP was validated using the forward primer sequence 5’- 
GCGCAGTAGTCCAGGGTTTCCTTGATGATG -3’ and the reverse primer sequence 5’- 
AGAATTTGCTGGAGGGCACAGACGTTTGGG -3’ and gave a ~ 400 bp product (data not 
shown). 
 
Histology, immunofluorescence, and immunocytochemistry. Kidney sections fixed in 4% 
paraformaldehyde overnight, were embedded in paraffin blocks and sectioned onto microscope 
glass slides. For immunofluorescence, tissues were deparaffinized, rehydrated, and subject to 
antigen retrieval with Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA). 
Tissues were incubated with primary antibodies overnight at 4°C and secondary antibodies for 
one hour at room temperature. For immunocytochemistry, ADPKD and NHK cells were grown 
on 25 mm glass coverslips (Fisher Scientific, PA). At 75% confluency, cells were serum-
deprived for 24 h and treated as indicated. Cells are then fixed in 4% paraformaldehyde and 
stained with the αVβ3 (Merk Millipore, MA; MAB1976) and corresponding anti-mouse IGG 
(H+L) - CS 4408; or with phalloidin to stain actin fibers (ThermoFisher Scientific; A12379). The 
following primary antibodies were used to stain renal tissues: Ki-67 (ab15880 and blocking 
peptide ab15881), periostin (Origene, Rockville, MD; TA500070,), P-S6 (CS 4858), and 
corresponding secondary antibodies (ab 150084, CS 4408). Sections were co-stained with FITC 
or rhodamine-conjugated Dolichos biflorus agglutinin (DBA; FL-1031 or RL-1032, Vector) to 
label CD cells and mounted with a mounting agent that contained DAPI (ThermoFisher 
Scientific; P36931). Slides were coded to deindentify the genotype and three non-overlapping 
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fields were imaged per section using a Nikon Eclipse Ti microscope. Nuclear Ki-67 and 
cytoplasmic P-S6 staining were quantified using the multi-wavelength cell scoring application in 
Metamorph Image Analysis software. 
 
 Measurement of renal cystic area. Slides mounted with tissue sections were coded, stained with 
hematoxylin and eosin, and imaged using a dissecting microscope (Leica Microsystems, Buffalo 
Grove, IL) connected to a digital color camera. A tubule dilation of 0.002 mm^2 was considered 
as a cyst. The total number of cysts, cystic area, and the total area of the kidney were measured 
using Image Pro Premiere (Media Cybernetics Inc, Silverspring, MD) as described previously 5. 
 
Measurement of tissue fibrosis. Masson’s trichrome was used on tissue sections to visualize 
collagen fibers (blue) 5 and pre-fibrotic edematous areas characterized by an increase in spacing 
between tubules (pale blue). Representative images were captured post-analysis using a Nikon T-
DH microscope attached to a digital color camera. Tissues sections were scored by a naïve 
observer assigning a percentage of fibrotic/edematous cortical area per total area of the cortex. 
PostnTG pcy mice develop modest fibrosis by 10 wk.  
  
Measurement of blood urea nitrogen (BUN). Blood was collected by cardiac puncture from 
experimental mice at the time of euthanasia. Serum was isolated by centrifugation at 10,000 
RPM for 10 min. A colorimetric QuantiChrom urea assay kit (DIUR 100; Bioassay Systems, 
Hayward, CA) was used to quantitate urea concentration, and BUN was calculated using the 
formula BUN = (Urea/2.14).  
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Statistics. Data are expressed as mean ± standard error (SE). Statistical significance was 
determined by unpaired t-test for comparisons between two experimental groups. For 
comparisons between multiple experimental conditions, one-way analysis of variance (ANOVA) 
followed by Student-Newman-Keuls (SNK) post-test was used. The Gehan-Breslow analysis 
was performed to determine statistical significance for survival studies. Pairwise analysis of the 
survival curves was performed using the Bonferroni method. 
 
4.4. Results 
4.4.1. The role of periostin in cytoskeletal reorganization in ADPKD cells.  
Previously, we showed that periostin promotes the proliferation of human ADPKD cells, 
but not normal human kidney cells. This difference in the response is likely due to differences in 
the expression of αV-integrin, the receptor for periostin2. To determine if periostin induces 
structural changes in the actin cytoskeleton, ADPKD cells were treated with periostin for 1 h and 
actin was visualized using phalloidin conjugated to green fluorescent protein. Periostin caused 
stress fiber formation and bundling of actin filaments into transverse and ventral stress fibers. 
(Figure 4-1). We also found integrin-clustering with an accumulation of αV-integrins at focal 
adhesion junctions 249. The formation of mature focal adhesions is responsible for ECM-integrin 
interaction to the actin cytoskeleton. Activation of focal adhesion kinase (FAK) is a rapid event 
in mature focal adhesions and promotes cell motility and actin cytoskeletal changes by activating 
Rho-family GTPases 250, 251. Periostin induced tyrosine phosphorylation of FAK (Figure 4-2) 
and activation of RhoA, a small Rho-family GTPase. To examine cell motility, we measured the 
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migration of ADPKD cells following a scratch in the monolayer. Periostin accelerated wound 
healing by increasing the rate of cell migration in ADPKD cells by 42% (Figure 4-3); however, 
periostin had no effect on NHK cells (Figure 4-4). HGF was used as a positive control and 
accelerated the migration of both ADPKD and NHK cells. These results suggest that periostin 

















Figure 4-1. Effect of periostin on actin stress fiber formation and αVβ3-integrin clustering. Primary 
cells derived from human ADPKD kidneys were treated with control media (A, C) or 250 ng/ml 
recombinant periostin (B, D) for 1 h. (A, B) Cells were stained with phalloidin to visualize F-Actin fibers 
(green), and nuclei were stained with DAPI (blue). Arrows indicate the formation of the actin stress fibers. 
(C, D) Integrin clustering was determined by staining with αVβ3-integrin antibody (red). Arrows indicate 









Figure 4-2. Effect of periostin on the activation of FAK and Rho signaling in ADPKD cells. Human 
ADPKD cells were incubated in media containing periostin for 15 min. Immunoblot analysis was used to 
measure the levels of phosphorylated FAK to total FAK. A representative immunoblot is shown. Bar graph 
represents mean and standard error (S.E) of phosphorylated FAK (P-FAK)/ total FAK, normalized to 
control (set to 1.0). Rho was immunoprecipitated from cell lysates using GST-RBD beads that have a high 
affinity for GTP-bound Rho. For negative control, GDP was loaded before immunoprecipitation to 
inactivate endogenous Rho. The immunoprecipitate and the whole cell lysates were immunoblotted for 
Rho. Bar graph represents mean and S.E of GTP-bound Rho to total Rho, normalized to control (set to 










Figure 4-3. Effect of periostin on ADPKD cell migration. Confluent cell monolayers were scratched and 
then treated with control media (A and B), periostin (C and D) or 40 ng/ml HGF (images not shown). 
Representative images of ADPKD cell migration 4 h (A and C) and 8 h (B and D) post-wounding. (E) The 
graph represents the quantification of the cell migration between 4 h and 8 h post-wounding. **P < 0.01, 
*P< 0.05, versus control treatment. 
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Figure 4-4. Effect of periostin on NHK cell migration. Confluent NHK cell monolayers were scratched, 
and then treated with control media (A and B), 250 ng/ml periostin (C and D) or 40 ng/ml HGF (images 
not shown). Representative images of NHK cell migration 4 h (A and C) and 8 h (B and D) post-
wounding. (E) Graph represents the quantification of the cell migration between 4 h and 8 h post-



















4.4.2. Periostin-induced gene expression changes in ADPKD cells.  
We sought to determine if periostin changes genes involved in tissue repair. We grew 
ADPKD cell monolayers grown on transwell supports were treated with periostin or control 
media for 24 h. Changes in the expression of 220 genes for integrin signaling, cytoskeletal 
remodeling and growth factor signaling were determined by quantitative real-time PCR analysis 
using Biorad PrimePCR array panels and gene changes were analyzed by the BioRad CFX 
manager. Periostin differentially regulated genes (Table 4-1) involved in ECM production 
(collagens type I and IV), cytoskeletal remodelling, including integrins (αV and β3 ; Figure 4-5) 
and elements of actin cytoskeleton (β- Actin, Actinins, and Filamin), focal adhesion proteins 
(ILK, AKT and β- catenin), and some molecules involved in growth factor signaling (SRC, 
GRB2, ATF1, RAF1 and MAP3K1), consistent with periostin-mediated activation of pathways 
involved in tissue repair. Interestingly, there was a significant decrease in the expression of 




Table 4-1. Periostin-induced gene regulation in ADPKD cells. Human primary ADPKD cells (N = 3 
kidney preparations) were grown on transwells to form polarized epithelial monolayers. Cells were treated 
with or periostin for 24 h. Total cellular RNA was isolated and reverse transcribed. mRNA levels of 220 
genes involved integrin outside-in signaling were detected using pre-designed PrimePCR arrays. The 
results were analyzed using Bio-Rad CFX Manager software. The genes that showed greater than ± 1.5-
fold change in gene regulation, with a p-value less than 0.05 are represented here. The expression changes 



















Figure 4-5. Effect of periostin on the expression of integrins αV, β1 and β3 in ADPKD and NHK cells. 
2 ADPKD and NHK cell preparations were grown on transwells and were treated with or without periostin 
for 24 h. The protein levels of αV, β1 and β3 integrins were estimated by immunoblot analysis and 
normalized to relative levels of GAPDH. N = 2 ADPKD kidneys.  
 90 
4.4.3. Generation of mice with CD-specific overexpression of periostin.  
We generated periostin transgenic mice (Postntg), which allow tissue-specific 
overexpression of periostin (Figure 4-6). To obtain CD-specific expression of periostin, we 
crossed the Postntg mice to Pkhd1-Cre mice 226. We confirmed periostin overexpression by 
immunoblot analysis of 10-wk-old mouse kidneys from Postntg;Pkhd1-Cre (PostnTG) mice 
(Figure 4-6 B). The littermate wildtype (WT) mice (Postntg and Pkhd1-Cre mice) did not 
express periostin, consistent with our previous observations 5. CD-specific expression of the 
PostnTG mice was visualized by immunofluorescence (Figure 4-6 C, D) using antibodies to 
periostin (green, ECM staining) and AQP-2 (red; a CD marker). Kidney sections from PostnTG 
mice expressed periostin in the ECM adjacent to the CD cells. By contrast, WT kidneys did not 
display periostin expression, consistent with earlier observations 5. At 10 weeks, we did not see 
cysts or the development of interstitial fibrosis in PostnTG mice, suggesting that periostin 









Figure 4-6. Collecting duct (CD)-specific overexpression of periostin. (A) We generated a transgenic 
mouse carrying a full-length periostin cDNA construct adjacent to a floxed mCherry stop cassette, 
downstream of the Rosa26 promoter. These mice were bred to Pkhd1-Cre mice to selectively express 
periostin in the CD. (B) To confirm Cre-mediated transgene expression, protein lysates from WT and 
PostnTG mice were immunoblotted for periostin. Conditional media (CM) from M1 cells transfected with 
full-length mouse periostin cDNA (mPostn) was used as positive control for periostin expression. Sections 
were stained for periostin (green), AQP-2 (CD marker) and DAPI (nuclear stain). (C) WT, (D) PostnTG. 
Scale bar = 5 µm. 
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4.4.4. Effect of periostin overexpression in the cyst-lining cells of pcy mice  
To determine if persistent overexpression of periostin in the cyst-lining cells accelerates 
PKD progression in pcy mice, we crossed Postntg and Pkhd1-Cre mice to pcy mice to obtain 
Postntg;Pkhd1-Cre;pcy/pcy (PostnTG pcy) mice and littermate pcy mice. At 10 and 30 wk, male 
PostnTG pcy and pcy mice were euthanized, and body weight, KW(%BW) and cystic index were 
measured (Figure 4-7, Figure 4-10). Periostin overexpression was visualized by 
immunofluorescence using an antibody to periostin (green), and CD cells were indicated by 
AQP-2 (red). Pcy mice have elevated expression of periostin compared to WT mice (Figure 
4-7). In the Postntg pcy mice, there was a much higher expression of periostin in the renal cystic 
epithelia compared to pcy mice lacking the transgene. At 10 wk, PostnTG pcy mice had a 38% 
increase in KW(%BW), compared to the kidneys of pcy littermates, with no effect on body 
weight. There was also a significant increase in cystic area and number of cysts in PostnTG pcy 







Figure 4-7. Effect of CD-specific periostin overexpression on kidney weight and cystic index in pcy 
mice. At 10 weeks, sections were stained for periostin (green), AQP-2 (CD marker) and DAPI (nuclear 
stain). (A) pcy, (B) PostnTGpcy. Scale bar = 5 µm. (C) Representative images of kidney cross-sections from 
10 wk old pcy and PostnTG pcy. Images were taken at the same magnification. Scale Bar = 1 mm. (D) 
Overexpression of periostin in CD cells had no effect on body weight. However, there was a significant 
increase in (E) kidney weight (% BW), (F) cystic index and (G) cyst number per section in PostnTG pcy (N 
= 8) mice compared to pcy (N = 6) mice. *P < 0.05, **P < 0.01 compared to pcy mice.  
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Next, we determined if CD-specific periostin overexpression increased cell proliferation. 
The number of Ki-67 positive cells per total nuclei was evaluated by immunofluorescence 
(Figure 4-8 A, B). Overexpression of periostin in the PostnTG pcy mice increased renal cell by 
2.1-fold. (Figure 4-8 C). Tissue sections from PostnTG pcy and pcy mice were stained with 
Masson Trichrome to visualize the collagen fibers and were scored for interstitial fibrosis 
(Figure 4-8 D, E). pcy mice that overexpressed periostin showed a 60% increase in interstitial 
damage (Figure 4-8 F) with more pathologic fibrosis (blue color), compared to littermate pcy 
mice.  
Previously, we found that periostin-induced cell proliferation and cyst growth was 
mediated by ILK signaling to the Akt/mTOR signaling pathway 245. In the current study, pcy 
mice displayed increased renal levels of P-S6 5, consistent with previous studies. Further, the 
level of phosphorylated S6 (P-S6) was two-fold higher in the PostnTG pcy mice compared to pcy 
littermates demonstrating that periostin overexpression further increased mTOR signaling in 






Figure 4-8. Effect of CD-specific periostin overexpression on renal cell proliferation and fibrosis in 
pcy mice. Proliferating cells were measured in kidney sections from (A) pcy and (B) Postntg;Pkhd1-
Cre;pcy (PostnTG pcy) mice that were stained for Ki-67 (red), DBA (green) and DAPI (blue). Arrows 
indicate Ki-67 positive cells. Images (A, B) were taken at the same magnification. Scale bar = 5 µm. (C) 
Comparison of nuclear Ki-67 staining in pcy and PostnTG pcy sections, normalized to total nuclei. 
Representative kidney sections from (D) pcy and (E) PostnTG pcy mice were stained with Masson’s 
trichrome to visualize edema and interstitial fibrosis. Scale bar = 50 µm. (F) Percentage of interstitial 





Figure 4-9. Effect of CD-specific overexpression of periostin on mTOR signaling in pcy kidneys. 
Representative sections from (A) pcy and (B) Postntg;Pkhd1-Cre;pcy (PostnTG pcy) sections mice stained 
with an antibody to P-S6 (red). Tissues were also stained with DAPI nuclear stain (blue). Arrows indicate 
cytoplasmic P-S6 in cyst-lining cells. All images were taken at the same magnification. Scale bar = 5 µm. 
(C) Percentage of cytosolic P-S6 positive cells normalized to the total nuclei. *P < 0.05 compared to pcy 
mice. 
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At 30 wk of age, PostnTG pcy mice showed a remarkable increase in KW(%BW) and a 
significant increase in the cystic index, compared to pcy mice (Figure 4-10). Previously, we 
showed that KW(%BW) of pcy mice plateaus by 20 wk due to fibrosis 228; however, 
overexpression of periostin causes the kidneys to continue to enlarge despite elevated fibrosis. 
This indicates that overexpression of periostin maintains the cystic cells in a state of 
proliferation. Renal function was assessed at 10 and 30 wk by measuring blood urea nitrogen 
(BUN) levels from the serum samples collected (Figure 4-10 D). At 10 wk, pcy mice have 
relatively normal BUN. Overexpression of periostin in the CD of pcy mice caused an increase in 
BUN; however, this trend was not significant. At 30 wk, BUN levels of pcy mice are elevated 
consistent with the decline in normal parenchyma. Overexpression of periostin caused a 
significant elevation in BUN compared to pcy mice, indicating that overexpression of periostin 
worsened renal function.  
Furthermore, we found that overexpression of periostin reduced the lifespan of pcy mice 
by 3 wk and the mice survived only ~ 45 wk, compared to littermate pcy mice, which survived to 
about 48 wk (Figure 4-11). These data suggest that CD-specific overexpression of periostin 
induces mTOR-mediated cell proliferation, increases the number of cysts and cystic area, 



















Figure 4-10. Effect of CD-specific periostin overexpression on kidney weight and cystic index in pcy 
mice at 30 wk. At 30 weeks, mice were euthanized, and kidneys were harvested. (A) Representative 
images of kidney cross-sections from 30 wk old pcy and Postntg;Pkhd1-Cre;pcy (PostnTG pcy) mice. 
Images were taken at the same magnification. Scale Bar = 5 mm. Overexpression of periostin in CD cells 
had no effect on body weight (data not shown). However, there was a significant increase in (B) kidney 
weight (% BW), and (C) cystic index in PostnTG pcy mice compared to pcy mice. N = 4 mice per group. 
(D) At 10 and 30 wk, blood was collected by cardiac puncture before euthanasia, and BUN was measured 
to assess renal function. BUN was not elevated in the pcy mice at 10 wk due to significantly preserved 
renal parenchyma at this age. *P < 0.05, **P < 0.01, compared to 30 wk pcy mice, and #P < 0.05, compared 



















Figure 4-11. Effect of periostin overexpression on the survival of pcy mice. (A) pcy mice and 
Postntg;Pkhd1-Cre;pcy (PostnTG pcy) mice were given standard chow and water ad libitum and regularly 
monitored until moribund. The graph shows Gehan-Breslow survival curves of mice. (B) The graph 
represents a summary of the ages of pcy mice (N = 9), and PostnTG pcy (N = 10), at the time of death. *P < 
0.05 compared to pcy mice.  
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4.5. Discussion 
In PKD, cystic epithelial cells are characterized as being incompletely differentiated with 
elevated expression of c-myc proto-oncogene and Akt/mTOR activity, contributing to aberrant 
cell proliferation and cyst growth 107, 115, 116, 118. It has been hypothesized that functional loss of 
the polycystins induces a cellular repair response to rectify the cystic phenotype 120. Due to the 
underlying gene mutation, this effort becomes futile, and the activation of these pathways 
accelerates the progression of disease. We found that aberrant expression of periostin, a repair 
molecule, by cystic epithelial cells increases the ILK-Akt-mTOR signaling pathway and cell 
proliferation, and contributes to cyst growth and fibrosis in PKD mice 2, 5, 245.  
Periostin is expressed in several tissues following injury and promotes tissue remodeling 
and repair 8, 131, 135, 165, 242, 252-254. In this study, we found that periostin caused actin stress fiber 
formation, integrin clustering, activation of FAK and Rho signaling, and cell migration. This is 
consistent with previous evidence for aberrant activation of Rho and FAK signaling in PKD 95, 
118. Moreover, periostin induced gene expression of ECM molecules, integrins, components of 
focal adhesion and the actin cytoskeleton, and molecules involved in growth factor signaling, 
consistent with cellular responses in tissue repair.  
Studies have shown that renal injury accelerates disease progression in slowly 
progressive models of PKD 121-125; however, the mechanism remains unclear. We found that 
persistent overexpression of periostin increased mTOR-mediated cell proliferation, cyst growth, 
fibrosis, and reduced the survival of PKD mice. Recently, periostin expression was found to be 
highly elevated in models of kidney injury 136, 243, 244, 246. We propose that the expression of 
periostin activates tissue repair mechanisms that promote cyst growth and fibrosis, further 
exacerbating the disease.  
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Overexpression of periostin did not result in any abnormal renal phenotype in wildtype 
mice. Similarly, periostin had no effect on mTOR activity or the proliferation of normal human 
kidney cells 2. We determined that ADPKD cells had a 9-fold higher expression of αV-integrin, 
the receptor for periostin, thus accounting for the difference in the periostin response. In fact, 
several integrin receptors including αv, β3, β1, and β4 have been shown to be upregulated in PKD 
and, therefore, may be involved in predisposing the cells to misregulated signals from the ECM 2, 
143, 154. Consistent with our hypothesis that aberrant expression of ECM contributes to cystic 
disease, laminin-332 (laminin-5), an ECM molecule overexpressed in PKD, promotes cell 
proliferation, adhesion and migration 143, 155. 
In summary, periostin overexpression in PKD exacerbates cyst growth and fibrosis by 
regulating genes and pathways involved in tissue repair, including cell proliferation, cytoskeletal 
remodeling, and matrix production (Figure 4-12). We propose that blockade of ECM-integrin 










Figure 4-12. Periostin promotes futile repair in PKD. Matricellular molecules including periostin, bind 
integrin receptors to activate pathways involved in futile repair. Integrin engagement activates ILK 
signaling to Akt and mTOR, leading to ADPKD cell proliferation. Alternatively, integrin engagement 
leads to activation of FAK and Rho mediated cytoskeletal remodeling and ADPKD cell migration. These 
tissue repair pathways are persistently activated by matricellular molecules including periostin. 
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CHAPTER 5. SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
5.1. Summary  
ADPKD affects over 150,000 people in the US and 12.5 million worldwide and has a 
devastating effect on the families as well as the national health care system 20. Therapeutic 
strategies for the treatment of ADPKD must consider the balance between drug efficacy and 
potential adverse effects due to long-term treatment 87, 255. A better understanding of the disease 
is necessary to develop novel targeted therapies to alter the course of the disease. 
Extracellular matrix (ECM) proteins not only make up components of the fibrotic scar 
but are also active regulators of tissue remodeling via cell-matrix signaling and may be involved 
in unchecked repair mechanisms that contribute to aberrant cell proliferation, cyst expansion, and 
fibrosis, ultimately leading to renal failure. Periostin, a tissue repair molecule, is persistently 
upregulated in PKD 2, leading to increased cyst growth and fibrosis. Gene knockout of periostin 
significantly improved renal function and survival of pcy/pcy mice, a slowly progressive murine 
model of PKD 5. Based on these observations, we reasoned that periostin and its associated 
signaling pathways are potentially viable targets for therapy.  
We demonstrated that treatment of human primary ADPKD cells with periostin increased 
the activity of integrin-linked kinase (ILK), a key mediator of integrin signaling, by 1.5-fold. 
There was also an increase in periostin-induced phosphorylation of Akt and S6 kinase (S6K), a 
downstream target of mTOR. The proliferative effect of periostin on PKD cells was blocked in 
the presence of an αv-integrin blocking antibody 2. From these results, we hypothesized that 
periostin-induced cell proliferation and cyst growth in PKD is mediated by activation of ILK and 
its downstream signaling targets, Akt, and mTOR. We reasoned that targeting ILK signaling will 
effectively block aberrant signals from ECM molecules including periostin, and delay PKD 
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progression. Pharmacological inhibition of ILK and shRNA knockdown of ILK blocked 
periostin-induced phosphorylation of Akt and S6K and prevented periostin-induced ADPKD cell 
proliferation. In contrast to ILK inhibition, shRNA knockdown of ILK also decreased EGF-
induced ADPKD cell proliferation. We reasoned that shRNA knockdown of ILK disrupted the 
interaction between receptor tyrosine kinase (RTK) and the ILK-Pinch-Parvin (IPP) complex 192, 
230, 231.  
Postnatal ablation of ILK in collecting ducts (CDs) caused a urinary concentrating defect, 
a decline in body weight, and the mice died by ten weeks of age. Complete loss of ILK (Ilk-/-) 
appeared to disrupt the connection between the ECM and cell cytoskeleton, a process called 
anoikis, leading to shedding of CD cells into the lumen, tubule obstruction, and dilation. By 
contrast, mice with a heterozygous deletion of ILK in the CDs (Ilk+/-) seemed normal with no 
apparent renal deficiency. Our results indicate that ILK is crucial for renal development, 
maintenance, and function, and corroborates previous findings that ILK is essential for renal 
development and function 205, 211.  
Next, we determined if CD-specific knockdown or knockout of ILK reduced cystic 
disease progression in ADPKD mice. We used 1) Pkd1fl/fl;Pkhd1-Cre mice, an aggressive 
orthologous model of ADPKD with a survival age of ~ 33 days and 2) pcy/pcy (pcy) mice, a 
slowly progressive model of PKD with a survival age of about 45 wk. Since mice with complete 
loss of ILK in the CDs died by 10 weeks, we did not generate Ilk-/- pcy mice. Pkd1fl/fl;Pkhd1-Cre 
mice with complete ablation of ILK (Ilk-/-) had a significant reduction in cystic burden. Upon 
examination, these mice showed increased apoptosis (anoikis) of the CD cells, causing the cells 
to be shed into the lumen. However, the renal function of these mice remained compromised due 
to the loss of ILK. Therefore, the reduction in cystic burden did not translate into an 
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improvement in survival. More importantly, we observed that deletion of one allele of ILK (Ilk+/-
) in the CDs was sufficient to decrease cyst growth, renal Akt/mTOR activity, and interstitial 
fibrosis, and significantly extended the survival of both models of PKD. ILK inhibitors have 
been shown to reduce carcinogenic cell proliferation and were also effective in reducing renal 
fibrosis 213, 237. However, due to the important role of ILK in the maintenance of normal renal 
function, pre-clinical studies should carefully document and monitor the effects of long-term use 
of ILK inhibitors.  
The work outlined in the first part of the dissertation demonstrates that 1) ILK is an 
important intermediate of periostin-induced cell proliferation and cyst growth in PKD and that 2) 
the ECM-ILK- mTOR pathway plays a crucial role in promoting cyst growth and fibrosis in 
PKD.  
Periostin is involved in a multitude of functions in different cellular contexts. 
Predominantly, periostin binds αV-integrins on the cell surface and activates cellular pathways 
involved in cell proliferation, survival, and profibrotic TGF-β signaling 2, 8, 137, 164, 169-171. 
Periostin also interacts with and regulates components of the ECM, including collagen and 
fibronectin, and promotes collagen cross-linking, which is important for tissue integrity 167, 168. 
Our lab was the first to demonstrate the involvement of periostin in a kidney disease. 
Considering that ADPKD cells have a cellular phenotype consistent with tissue repair and that 
periostin is expressed during tissue repair, we hypothesized that persistent expression of periostin 
by the cyst-lining epithelia, triggers tissue repair pathways in PKD, accelerating cyst growth and 
fibrosis. 
We found that periostin induced, signature molecular patterns pertaining to cytoskeletal 
rearrangement, including actin stress fiber formation, and integrin clustering. Integrin clustering 
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promotes the formation of mature focal adhesions responsible for ECM-integrin interaction and 
cell migration 249-251. Periostin induced tyrosine phosphorylation of focal adhesion kinase (FAK) 
and activated the Rho-family GTPases (Rho). Further, periostin promoted cell migration in 
ADPKD cells, but not NHK cells. Next, we determined if periostin regulated genes involved in 
renal repair. In ADPKD cells, periostin treatment induced the expression of molecules involved 
in actin assembly, focal adhesion formation, ECM production and integrin signaling.  
Finally, we determined if the overexpression of periostin in the CDs accelerates PKD 
progression. To this end, we generated pcy mice with ectopic expression of periostin in the CDs. 
Periostin overexpression accelerated the progression of the cystic disease by significantly 
increasing renal mTOR activity, cell proliferation, cyst growth and interstitial fibrosis. By 
contrast, wild-type mice with CD-specific periostin overexpression did not display any 
phenotype, supporting the idea that a prior genetic insult in the kidney is required for periostin 
pathogenesis. Preliminary immunoblot analysis indicated that the renal levels of periostin 
expression in the transgenic mice were equivalent to the physiological levels of periostin 
expression in mice hearts. While this indicates that physiological levels of periostin is sufficient 
to accelerate disease, it could also explain why we do not see a dramatic increase in disease 
progression at ten weeks in pcy mice. By 20 weeks of age, pcy mice already have a 20-fold 
overexpression of periostin compared to control mice 5. We speculate that the already elevated 
expression of periostin accelerates the disease progression and masks the effect of the transgene 
expression since there was only a small decline in survival with periostin overexpression.  
Our work demonstrates that aberrant expression of periostin in PKD appears to promote 
pathways involved in tissue repair, including proliferation, cytoskeletal remodeling and ECM 
deposition, leading to increased mTOR-mediated cell proliferation, and fibrosis. 
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5.2. Future Directions 
Our long-term goals are to delineate the cellular and molecular mechanisms underlying 
the mitogenic and fibrotic effects of matricellular molecules including periostin, in renal cystic 
diseases. This work has led us to several potential future directions.  
• TGF-β, the master cytokine responsible for ECM production 137 is elevated in the cystic 
epithelia of most human and rodent forms of PKD and is heavily implicated in accelerating 
PKD progression 147. Previously, we found that TGF-β increases periostin expression in renal 
epithelial cells 2. In addition to being involved in periostin activation of ILK and its 
downstream pathways, αV-integrin appears to regulate the release of the active form of TGF-β 
256, 257. We can determine the interplay between periostin, αV-integrin, and TGF-β in ADPKD. 
We could also determine if periostin is involved in the direct activation of the TGF-β 
signaling pathway.  
• We generated periostin transgenic mice (Postntg), which allow tissue-specific overexpression 
of periostin (Figure 4-6). We observed that CD-specific overexpression of periostin in wild-
type mice did not cause any pathologies. Recently, periostin was also shown to be 
overexpressed in glomerular injury, hypertensive nephropathy and diabetic nephropathy 136, 
243, 244, supporting the idea that aberrant expression of periostin is an injury response. Our 
work was the first to identify a role for periostin in renal pathology. However, currently, there 
is very little known about periostin in the pathogenesis of other chronic kidney diseases. Our 
Postntg mice is a highly useful tool to study the effects of aberrant periostin expression in 
CKD. 
 108 
• Recently, Morra et al. have identified about eight splice variants of periostin from fetal 
kidneys and tissue samples of renal cell carcinoma patients 166. While the splice variants in the 
C-terminus might not affect integrin binding, it has been speculated that they may play a role 
in tumor metastasis in cancers by influencing the ECM composition. Despite the massive 
enlargement of the kidneys due to cysts, there is surprisingly very few cases of kidney cancers 
in PKD patients 258. Identifying periostin splice variants in PKD uncover a better 
understanding of its pathogenic functions, such as proliferation, fibrosis, and metastasis. 
Identifying periostin splice variants in PKD holds potential since it is possible that different 
splice variants may be responsible for various pathogenic functions, such as proliferation and 
fibrosis.  
• We have demonstrated that periostin binds to the integrin receptors and activates ILK 
signaling to the Akt/ mTOR pathway in PKD. Based on these observations, we have identified 
some potential therapeutic targets (Figure 5-1) 1) ILK: Recently, Li et al. showed that ILK 
inhibitors could be effectively used in a mouse model of obstructive nephropathy to reduce 
TGF-β-induced renal fibrosis 237. However, ILK may be a difficult therapeutic target for long-
term treatment, since it is critical for maintaining the renal parenchyma 205, 211, 245. 2) Integrin 
antagonists: We showed that αV-integrins are upregulated in PKD and can remain persistently 
upregulated due to the aberrant repair signals from the ECM. Cilengitide, an αV-integrin 
antagonist, has been extensively studied in cancer and may be a potential therapeutic target for 
PKD 259. 3) ECM molecules: We have demonstrated that targeting aberrant periostin 
expression in PKD could significantly reduce cyst growth and fibrosis. Ma et al.260, recently 
showed that abrogation of fibronectin reduced the progression of PKD. ECM molecules such 
as laminin are also aberrantly expressed in PKD and contribute to increased cell adhesion, 
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migration and proliferation 143, 155. The use of antisense oligonucleotides to target secreted 
molecules in PKD is intriguing. Recently, Mael-Ainin et al. successfully used periostin 
oligonucleotides to treat L-NAME-induced tubular injury in mice 261. 
 
5.3. Conclusions 
Our data elucidates certain molecular mechanisms involved in periostin-mediated PKD 
progression, highlighting the role of ILK signaling in PKD. Our results indicate that aberrant 
expression of periostin stimulates integrin-ILK signaling and promotes cell proliferation, 
cytoskeletal rearrangement and migration, and ECM production. Targeting ECM-integrin 
signaling may hold significant therapeutic potential in PKD. Our results also provide a 








Figure 5-1. The role of matricellular signaling in PKD. ECM molecules including periostin, bind 
integrin receptors to activate pathways involved in futile repair. Integrin engagement activates ILK 
signaling to Akt and mTOR, leading to ADPKD cell proliferation. Integrin engagement also leads to 
activation of FAK and Rho mediated cytoskeletal remodeling, ADPKD cell migration and ECM 
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